US.LLY · Lilly (Eli)

{
  "risk": {
    "level": "Elevated",
    "reason": "risk management score >= 5/10",
    "position": {
      "score": 1.5,
      "details": {
        "atrPct": 3.5403485775131203,
        "turnoverUsdM": 3510.09354319545,
        "liquidityPoints": 0.8,
        "volatilityPoints": 0.7
      }
    },
    "rrPoints": 1.4,
    "stopLevels": {
      "symbol": "US.LLY",
      "rr_range": "1:1.0-1:2.5",
      "risk_profile": "中等",
      "stop_loss_price": 1074.7107,
      "strength_details": {
        "ma_score": 1.5,
        "atr_score": 1,
        "rsi_score": 2,
        "macd_score": 1.5,
        "volume_score": 1
      },
      "market_adjustment": 1,
      "risk_reward_ratio": 1,
      "stop_loss_percent": 7.1,
      "take_profit_price": 1218.8473,
      "target_multiplier": 1.6,
      "technical_strength": 1.43,
      "take_profit_percent": 5.4
    },
    "positionPoints": 1.5,
    "stopLossPoints": 1.2,
    "diversification": {
      "score": 2,
      "details": {
        "method": "sector concentration proxy; no portfolio holdings used",
        "sector": "Health Care",
        "concentratedSectorPenalty": 0
      }
    },
    "riskRewardRatio": 1.2,
    "stopLossPercent": 7.0806971550262405,
    "diversificationPoints": 2
  },
  "total": {
    "max": 160,
    "result": 55,
    "formula": "score_with_momentum_v2 = main_score + momentum_5d_v2_score",
    "baseScore": 52,
    "modelVersion": "cursor_18_27_news_v2_160",
    "momentum5dScore": 3
  },
  "market": {
    "ma20": 1168.9153,
    "ma50": 1101.5919,
    "close": 1156.61,
    "prevClose": 1152.54,
    "avgVolume20": 3100086,
    "volumeRatio": 0.98,
    "changePercent": 0.35
  },
  "sources": {
    "catalyst": "finnhub_news_keyword_model",
    "sentiment": "finnhub_news_keyword_model",
    "fundamentals": "fmp_stable",
    "institutional": null,
    "marketContext": "twelvedata+fred"
  },
  "barCount": 60,
  "momentum": {
    "max": 50,
    "result": 3,
    "details": {
      "ret_5d": -0.048710355846141584,
      "max_score": 50,
      "max_total": 50,
      "raw_total": 3,
      "vcp_bonus": 0,
      "vol_ratio": 0.9768616588958398,
      "ret_points": 0,
      "vol_points": 0,
      "range_ratio": 0.7498112038804579,
      "volat_points": 0,
      "day_range_pct": 0.022842627239369123,
      "model_version": "cursor_18_27_news_v2_160",
      "available_bars": 30,
      "breakout_points": 0,
      "partial_history": false,
      "pullback_points": 3,
      "breakout_vol_bonus": 0,
      "first_breakout_20d": false,
      "return_window_days": 5,
      "first_breakout_bonus": 0,
      "breakout_quality_points": 0
    },
    "formula": "Cursor_18.25 5D momentum v2 0-50",
    "modelVersion": "cursor_18_27_news_v2_160"
  },
  "scoreMax": 110,
  "composite": {
    "max": 160,
    "result": 55,
    "formula": "Cursor_18.25 ranking score v2 (score_with_momentum_v2)",
    "weights": [
      {
        "raw": 5,
        "label": "基本面",
        "weight": "5/110",
        "normalized": 100,
        "contribution": 5
      },
      {
        "raw": 7.6,
        "label": "資金流",
        "weight": "20/110",
        "normalized": 38,
        "contribution": 7.6
      },
      {
        "raw": 8.4,
        "label": "市場環境",
        "weight": "15/110",
        "normalized": 56,
        "contribution": 8.4
      },
      {
        "raw": 6,
        "label": "催化劑",
        "weight": "20/110",
        "normalized": 30,
        "contribution": 6
      },
      {
        "raw": 6.1,
        "label": "風險管理",
        "weight": "10/110",
        "normalized": 61,
        "contribution": 6.1
      },
      {
        "raw": 16.9,
        "label": "技術信號",
        "weight": "30/110",
        "normalized": 56.33,
        "contribution": 16.9
      },
      {
        "raw": 2,
        "label": "情緒分析",
        "weight": "10/110",
        "normalized": 20,
        "contribution": 2
      }
    ],
    "modelVersion": "cursor_18_27_news_v2_160"
  },
  "momentumMax": 50,
  "scoreStatus": "checked",
  "standard110": {
    "rating": "避免",
    "result": 52,
    "details": [
      "基本面分析總分: 5/5分",
      "資金流分析總分: 7.6/20分",
      "市場環境分析總分: 8.4/15分",
      "催化劑分析: 6/20分",
      "風險管理總分: 6.1/10分",
      "技術信號分析總分: 16.9/30分",
      "情緒分析: 2/10分",
      "共振率(僅顯示不加分): 0%"
    ],
    "formula": "基本面5 + 資金流20 + 市場環境15 + 催化劑20 + 風險管理10 + 技術信號30 + 情緒10",
    "dimensionScores": {
      "催化劑": 6,
      "基本面": 5,
      "資金流": 7.6,
      "市場環境": 8.4,
      "情緒分析": 2,
      "技術信號": 16.9,
      "風險管理": 6.1
    },
    "dimensionDetails": {
      "催化劑": {
        "max": 20,
        "grade": "較差",
        "items": {
          "catalyst": {
            "score": 6,
            "details": {
              "source": "finnhub_news_keyword_model",
              "articleCount": 8,
              "catalystCount": 1
            }
          },
          "catalystPoints": 6
        }
      },
      "基本面": {
        "max": 5,
        "grade": "優秀",
        "items": {
          "pbPoints": 0.2,
          "pePoints": 0.2,
          "epsPoints": 0.75,
          "roePoints": 0.75,
          "debtPoints": 0.4,
          "marginPoints": 0.75,
          "turnoverUsdM": 3510.09354319545,
          "volumePoints": 0.5,
          "revenuePoints": 0.75,
          "dividendPoints": 0.3,
          "marketCapPoints": 0.5
        },
        "source": "fmp_stable"
      },
      "資金流": {
        "max": 20,
        "grade": "較差",
        "items": {
          "cmfPoints": 1.6,
          "mfiPoints": 1.6,
          "obvPoints": 1.6,
          "vwapPoints": 0.8,
          "institutional": {
            "score": 2,
            "details": {
              "source": "optional-neutral",
              "warning": {
                "code": "INSTITUTIONAL_DATA_OPTIONAL",
                "symbol": "US.LLY",
                "message": "Institutional ownership is unavailable; neutral 2/4 money-flow treatment used."
              },
              "optional": true,
              "holderCount": null,
              "holderPoints": 2,
              "top10ShareRatio": null,
              "concentrationPenalty": 0
            }
          },
          "institutionPoints": 2
        }
      },
      "市場環境": {
        "max": 15,
        "grade": "較差",
        "items": {
          "vix": {
            "score": 2.4,
            "details": {
              "source": "twelvedata+fred",
              "vixClose": 16.5
            }
          },
          "trend": {
            "score": 2.4,
            "details": {
              "qqq": {
                "ma20": 720.8980038500001,
                "ma50": 718.06860224,
                "name": "QQQ",
                "close": 717.69,
                "points": 0.4
              },
              "spy": {
                "ma20": 744.8810085,
                "ma50": 743.3342028999999,
                "name": "SPY",
                "close": 754.72998,
                "points": 2
              },
              "source": "twelvedata+fred"
            }
          },
          "atrPct": 3.5403485775131203,
          "atrPoints": 2,
          "cciPoints": 1.6,
          "vixPoints": 2.4,
          "marketTrendPoints": 2.4
        }
      },
      "情緒分析": {
        "max": 10,
        "grade": "較差",
        "items": {
          "sentiment": {
            "score": 2,
            "details": {
              "source": "finnhub_news_keyword_model",
              "articleCount": 8,
              "negativeHits": 1,
              "positiveHits": 1,
              "sentimentScoreRaw": 0
            }
          },
          "sentimentData": {
            "raw": [
              {
                "id": 140911279,
                "url": "https://finnhub.io/api/news?id=0ca1c1856667dd70b66b3f69a7a38572ad4af4d10dff044da49f8c9d3c91e9d4",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Oral Wegovy is now cleared in all EU member states.",
                "category": "company",
                "datetime": 1784137749,
                "headline": "NVO Stock Jumps 3% As EU Approves Oral Wegovy Pill — Retail Notes LLY Is ‘Clearly Behind’ Its Danish Counterpart"
              },
              {
                "id": 140905696,
                "url": "https://finnhub.io/api/news?id=9acdd92ee551cbdda90c829dc3d0bd2375681e45cc8361c5fd49c1f910a68c42",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "FDA grants full approval to Eli Lilly's selpercatinib (Retevmo) for a wider group of adult and pediatric patients with RET fusion solid tumors. The decision shifts selpercatinib from accelerated to traditional approval and broadens its labeled use across multiple tumor types. The update reinforces Eli Lilly's (NYSE:LLY) position in oncology and opens new commercial and clinical avenues for the drug. Eli Lilly, known for its oncology and biopharma portfolio, now has a fully approved RET...",
                "category": "company",
                "datetime": 1784092274,
                "headline": "Eli Lilly (LLY) Wins Full FDA Approval For Retevmo In Broader Cancers"
              },
              {
                "id": 140904204,
                "url": "https://finnhub.io/api/news?id=d355869fae15f49968e962d9308dd96b767ce8afecabeef0d4860a8b611ae233",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Eli Lilly (LLY) reached $1 at the closing of the latest trading day, reflecting a -2.48% change compared to its last close.",
                "category": "company",
                "datetime": 1784065506,
                "headline": "Eli Lilly (LLY) Stock Dips While Market Gains: Key Facts"
              },
              {
                "id": 140895218,
                "url": "https://finnhub.io/api/news?id=ac09b1e825d85078efac14d5865d13b080a0223865d4193158494544f04990de",
                "image": "https://www.chartmill.com/images/uploads/thumbnail_article_navellier_3be8c6e05a.webp",
                "source": "ChartMill",
                "related": "LLY",
                "summary": "Louis Navellier’s eight-rule growth investing framework identifies stocks with strong earnings momentum and efficiency. Eli Lilly (LLY) passes this screen, showing exceptional sales, earnings, and cash flow growth.",
                "category": "company",
                "datetime": 1784022636,
                "headline": "Eli Lilly & Co. (NYSE:LLY) Passes Navellier’s High-Growth Screen on Strong Earnings and Sales Momentum"
              },
              {
                "id": 140885768,
                "url": "https://finnhub.io/api/news?id=beb87ad176efb9fdff630913987b4267d509627241251c66ccf0cea69cf5af22",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "At $1,189, Eli Lilly (LLY) looks set up for roughly 76% of upside over the next three years under a conservative scenario. That is a move large enough to justify digging into where it comes from. Revenue compounding does the work, but the multiple takes a meaningful cut along the way. Here is the operational reality the math is built on.",
                "category": "company",
                "datetime": 1783948326,
                "headline": "How Does LLY Stock Reach $2,100?"
              },
              {
                "id": 140868785,
                "url": "https://finnhub.io/api/news?id=1222dbd0e33abeb26678833c523058c9f542d2588c9d968ce5c8336f051c40b5",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Eli Lilly plans to present new Alzheimer's research at the 2026 Alzheimer's Association International Conference, including long term data on Kisunla (donanemab-azbt). The company will share updated safety and biomarker findings from its Kisunla program. Eli Lilly will also outline progress on blood based P-tau217 diagnostics that could support broader Alzheimer's screening. Eli Lilly, traded as NYSE:LLY, is set to bring fresh Alzheimer's data to the forefront, while attention has recently...",
                "category": "company",
                "datetime": 1783743328,
                "headline": "Eli Lilly (LLY) To Share New Kisunla And Alzheimer’s Blood Test Data At AAIC"
              },
              {
                "id": 140859133,
                "url": "https://finnhub.io/api/news?id=f3b3f970a75ff80e094b724eb87270ab4f26b82709f3ffaea915396f145b4708",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Biotech is gaining momentum as healthcare leads higher, with several drugmakers and life sciences companies showing improving earnings trends and breakouts.",
                "category": "company",
                "datetime": 1783665420,
                "headline": "Zacks Investment Ideas feature highlights: XLV, XBI, LLY, EXEL, PTCT, FTRE and ILMN"
              },
              {
                "id": 140848108,
                "url": "https://finnhub.io/api/news?id=83802d7c0c6cf8398ae3af9cf033877b0a4aec73cbd5ee80e3f87882e6d45d45",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Eli Lilly (LLY) keeps setting records, and Wall Street’s rating of its stock keeps increasing as well. On Tuesday, one of JPMorgan’s most closely watched healthcare stock analysts, Chris Schott, who frequently covers Pfizer Inc. (PFE), Eli Lilly, and Teva Pharmaceutical Industries Ltd. ...",
                "category": "company",
                "datetime": 1783573620,
                "headline": "JPMorgan resets LLY stock target on drug demand"
              }
            ],
            "raw_source": [
              {
                "id": 140914216,
                "url": "https://finnhub.io/api/news?id=b390ec668e38345dfeef3aff61fea4ff4198e1ed8c7c64c0564ef47c2491661b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Wegovy Pill Wins Big as Eli Lilly Rollout Lags",
                "category": "company",
                "datetime": 1784145879,
                "headline": "Novo Nordisk Stock Rises After Wegovy Pill Captured 89% of U.S. Prescriptions"
              },
              {
                "id": 140914217,
                "url": "https://finnhub.io/api/news?id=728eeda0f5cd114e57b2b33bdc9915750ee8c98f90d45e2c1a27ee97e48db7c1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Wegovy captured about 89% of weekly prescriptions.",
                "category": "company",
                "datetime": 1784145757,
                "headline": "Lilly's Obesity Pill Trails Wegovy"
              },
              {
                "id": 140912796,
                "url": "https://finnhub.io/api/news?id=5ccc34e4756d7738080b340739486447e99093318707e151a7d32d918ec99aee",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Healthcare stocks rose late Wednesday afternoon, with the NYSE Healthcare Index adding 0.3% and the",
                "category": "company",
                "datetime": 1784144857,
                "headline": "Sector Update: Healthcare Stocks Advance Late Afternoon"
              },
              {
                "id": 140911279,
                "url": "https://finnhub.io/api/news?id=0ca1c1856667dd70b66b3f69a7a38572ad4af4d10dff044da49f8c9d3c91e9d4",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Oral Wegovy is now cleared in all EU member states.",
                "category": "company",
                "datetime": 1784137749,
                "headline": "NVO Stock Jumps 3% As EU Approves Oral Wegovy Pill — Retail Notes LLY Is ‘Clearly Behind’ Its Danish Counterpart"
              },
              {
                "id": 140911280,
                "url": "https://finnhub.io/api/news?id=20b0d88f50adb6770ced929f134ea877401a5f178c1c8488b3933a62a362de03",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Healthcare stocks rose Wednesday afternoon, with the NYSE Healthcare Index adding 0.4% and the State",
                "category": "company",
                "datetime": 1784137282,
                "headline": "Sector Update: Healthcare Stocks Advance in Afternoon Trading"
              },
              {
                "id": 140911281,
                "url": "https://finnhub.io/api/news?id=94f35e15deebced35b04ff5c406ec8d6fd1ae0f0aa49c08462683383ce3c0bbe",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Roche wins FDA Priority Review for Gazyva in primary membranous nephropathy, with a decision due by November 2026 after positive phase III data.",
                "category": "company",
                "datetime": 1784131620,
                "headline": "RHHBY's Gazyva Gets FDA Priority Review for Label Expansion"
              },
              {
                "id": 140909556,
                "url": "https://finnhub.io/api/news?id=078bec1491fb0d2386bee78b68cb24d0e112102bf4d9c5e65ba67d4356afdbbf",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "BIIB's Alzheimer's drug data presentation reaffirms a phase II setback as investors weigh plans to advance diranersen in phase III despite missed goals.",
                "category": "company",
                "datetime": 1784127060,
                "headline": "Biogen Shares Decline After Detailed Diranersen Alzheimer's Study Data"
              },
              {
                "id": 140909557,
                "url": "https://finnhub.io/api/news?id=87c4cf90385ae76ab651add642a65e43416c03a34848a9841d154421a6af5dee",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "The milestone payment strengthens VivoSim’s cash position while management projects significant revenue growth driven by expanding demand for its human-based preclinical testing platform. Key Investor TakeawaysVivoSim (NASDAQ:VIVS) received a $5 million milestone payment from Eli Lilly tied to the advancement of a previously sold drug candidate into Phase 2 studies.",
                "category": "company",
                "datetime": 1784126810,
                "headline": "VivoSim Receives $5 Million Milestone Payment From Eli Lilly and Forecasts 500%+ FY2027 Revenue Growth"
              },
              {
                "id": 139941219,
                "url": "https://finnhub.io/api/news?id=f5af666d096d8f45d34d78bac257ee6d0c8030a696cc155fe2fc4bece3190a60",
                "image": "",
                "source": "Benzinga",
                "related": "LLY",
                "summary": "",
                "category": "company",
                "datetime": 1784120481,
                "headline": "Shares of several banks and financial services companies are trading higher amid overall market strength as investors anticipate this week's Fed Reserve meeting."
              },
              {
                "id": 140910531,
                "url": "https://finnhub.io/api/news?id=57000288ae8e34864fe003c9dc01032ef3345e614ac1f58d27e5e9465af2590c",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1365641802/image_1365641802.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "LLY",
                "summary": "AstraZeneca PLC Q2 2026 preview: revenue growth, Enhertu sales surge and EU approval, plus risk/reward after Wainua trial setback. Click for this AZN stock update.",
                "category": "company",
                "datetime": 1784120082,
                "headline": "AstraZeneca's Oncology Engine Keeps Running Despite Wainua Setback"
              },
              {
                "id": 140908136,
                "url": "https://finnhub.io/api/news?id=12e41338336f8c67eec77e854a143b296e63e02f393b5d4a57bc364fdfcd58eb",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Management jacked up its forecast in a way that's impossible to ignore, and while the stock has already ripped higher, the real debate is whether this is a new reality or a temporary sugar high.",
                "category": "company",
                "datetime": 1784119913,
                "headline": "Dell Stock Lit The Afterburners. Is There Enough Fuel For The Trip?"
              },
              {
                "id": 140911087,
                "url": "https://finnhub.io/api/news?id=e3877bf217cf9a3696a761c9f102d1877ba97d809c56c59d19aaa77754edfc0f",
                "image": "https://cdn.benzinga.com/files/images/story/2025/07/10/valuestock_2.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "LLY",
                "summary": "Eli Lilly (NYSE:LLY) has outperformed the market over the past 5 years by 25.47% on an annualized basis producing an average annual return of 37.22%. Currently, Eli Lilly has a market capitalization of $1.02 trillion.",
                "category": "company",
                "datetime": 1784118629,
                "headline": "If You Invested $1000 In Eli Lilly Stock 5 Years Ago, You Would Have This Much Today"
              },
              {
                "id": 140908240,
                "url": "https://finnhub.io/api/news?id=d3b6e5cb1540fdc9d39a278ae116d1281f06fc87e1f679128bae0211484e8823",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "SAN DIEGO, July 15, 2026 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the “Company” or “VivoSim”), a provider of next-generation New Approach Methodologies (NAM) 3d human cellular models for preclinical safety, today announced revenue guidance for FY2027, and announced that it has received a $5 million payment from Eli Lilly. In association with its former inflammatory bowel disease drug program developed previously and sold outright to Eli Lilly, VivoSim has received $5 million as a m",
                "category": "company",
                "datetime": 1784117100,
                "headline": "VivoSim Receives $5M Milestone Payment from Eli Lilly; Provides Guidance That It Expects Revenue Growth of 500%+ in FY2027"
              },
              {
                "id": 140911088,
                "url": "https://finnhub.io/api/news?id=b866d74ab0401557f0cf0728da580412a4e7b405ecbfc9c7ec38f00fcbfedc37",
                "image": "",
                "source": "Benzinga",
                "related": "LLY",
                "summary": "Citigroup  analyst Geoff Meacham   maintains Eli Lilly (NYSE:LLY) with a Buy and raises the price target from $1500 to $1600.",
                "category": "company",
                "datetime": 1784114487,
                "headline": "Citigroup Maintains Buy on Eli Lilly, Raises Price Target to $1600"
              },
              {
                "id": 140911089,
                "url": "https://finnhub.io/api/news?id=e27f979971abd25781adf4005863bf7dcc2291c17f7ae62c49370ce68f219b6e",
                "image": "https://cdn.benzinga.com/files/images/story/2026/07/15/Hands--Slide-And-Science-Closeup-For-Mic.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "LLY",
                "summary": "VivoSim Labs shares climbed after receiving a $5 million Eli Lilly milestone payment and forecasting more than 500% revenue growth in FY2027.",
                "category": "company",
                "datetime": 1784114424,
                "headline": "Why Vivosim Labs Shares Are Rocketing on Wednesday?"
              },
              {
                "id": 140907418,
                "url": "https://finnhub.io/api/news?id=19a91e27c907e4d474ed5f920d99f42f152b62d573c112f68960964509e02e31",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "(Bloomberg) -- AdvanCell Pty, a biotechnology firm backed by Eli Lilly & Co., has raised $315 million in new funding, underscoring investor confidence in its experimental cancer therapy.Most Read from BloombergThailand Scraps Plan to End Visa-Free Entry for Indian TouristsTrump Drops 20% Fee for Hormuz Cargo After Gulf PressureUS Hits Iran With Strikes, Blockade as Trump Plans Hormuz ChargeOpenAI’s First Device Will Be Movable, Screenless Speaker Built as AI Companion‘We Faltered’: IBM Plunges M",
                "category": "company",
                "datetime": 1784109600,
                "headline": "Eli Lilly-Backed Novel Cancer Therapy Firm Raises $315 Million"
              },
              {
                "id": 140911090,
                "url": "https://finnhub.io/api/news?id=f5cdcf87fd1a86ae3ecd1079b8e91ebecce0876162b6b4c797c84134488a8d83",
                "image": "",
                "source": "Benzinga",
                "related": "LLY",
                "summary": "VivoSim Labs, Inc. (Nasdaq: VIVS) (the "Company" or "VivoSim"), a provider of next-generation New Approach Methodologies (NAM) 3d human cellular models for preclinical safety, today announced revenue",
                "category": "company",
                "datetime": 1784102947,
                "headline": "VivoSim Labs Anticipates 500% Revenue Growth In FY27; Receives $5M Milestone Payment From Eli Lilly"
              },
              {
                "id": 140905696,
                "url": "https://finnhub.io/api/news?id=9acdd92ee551cbdda90c829dc3d0bd2375681e45cc8361c5fd49c1f910a68c42",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "FDA grants full approval to Eli Lilly's selpercatinib (Retevmo) for a wider group of adult and pediatric patients with RET fusion solid tumors. The decision shifts selpercatinib from accelerated to traditional approval and broadens its labeled use across multiple tumor types. The update reinforces Eli Lilly's (NYSE:LLY) position in oncology and opens new commercial and clinical avenues for the drug. Eli Lilly, known for its oncology and biopharma portfolio, now has a fully approved RET...",
                "category": "company",
                "datetime": 1784092274,
                "headline": "Eli Lilly (LLY) Wins Full FDA Approval For Retevmo In Broader Cancers"
              },
              {
                "id": 140904204,
                "url": "https://finnhub.io/api/news?id=d355869fae15f49968e962d9308dd96b767ce8afecabeef0d4860a8b611ae233",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Eli Lilly (LLY) reached $1 at the closing of the latest trading day, reflecting a -2.48% change compared to its last close.",
                "category": "company",
                "datetime": 1784065506,
                "headline": "Eli Lilly (LLY) Stock Dips While Market Gains: Key Facts"
              },
              {
                "id": 140901437,
                "url": "https://finnhub.io/api/news?id=85a7dde379b55c28caed39928be7f2f662379741b95f70f30eb6804a9b58aabe",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Eli Lilly and Company (LLY) on Tuesday received traditional approval from the US Food and Drug Admin",
                "category": "company",
                "datetime": 1784056545,
                "headline": "Eli Lilly Wins Full FDA Approval for Selpercatinib in Solid Tumors"
              },
              {
                "id": 140901438,
                "url": "https://finnhub.io/api/news?id=9fd95fbb80f47cce96cfbcae493bee66c1a8f0e6fab86029428940d7057e1de6",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "The presentation on  Biogen’s  experimental Alzheimer’s treatment at a medical meeting Tuesday was supposed to boost confidence in its drug’s prospects.  Instead, Biogen stock is down 6%, to $197.  Tuesday’s presentation on the drug diranersen, at London’s Alzheimer’s Association International Conference, left attendees confused about what to conclude from Biogen’s Phase 2 study known as CELIA.",
                "category": "company",
                "datetime": 1784052540,
                "headline": "Biogen’s Alzheimer’s Drug Leaves Questions Unanswered, and That’s a Problem"
              },
              {
                "id": 140901439,
                "url": "https://finnhub.io/api/news?id=64cd56311f93e5171b803be30ef3da8f9f5b6d1c652a2a55be30635d893b79a0",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "In the world of big pharma, one company is both the star performer and the most expensive name on the marquee, forcing investors to ask if the price of admission is simply too high.",
                "category": "company",
                "datetime": 1784051674,
                "headline": "What Lilly's Peer-Beating Numbers Cost You"
              },
              {
                "id": 140899731,
                "url": "https://finnhub.io/api/news?id=ab9efa283f15df1648247f3f9e34e0ef7c686344770d8bd769c997f910e901a6",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "BIIB secures FDA approval for Leqembi Iqlik, letting early Alzheimer's patients start with a weekly at-home autoinjector instead of biweekly IV infusions.",
                "category": "company",
                "datetime": 1784045640,
                "headline": "Biogen Wins FDA Approval for Subcutaneous Starter Dose of Leqembi"
              },
              {
                "id": 140899690,
                "url": "https://finnhub.io/api/news?id=9e7ebc357240455e6e55a9a903db00b21fce46bf6f2101bbe4e9afbcf279c728",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "While the company's AI spending commands attention, the real story is how the technology is already accelerating the core business that funds it all.",
                "category": "company",
                "datetime": 1784045347,
                "headline": "What Could Power The Next Rally In META Stock"
              },
              {
                "id": 140898040,
                "url": "https://finnhub.io/api/news?id=68a6715e91bd7ceaf0c6c6916c02776afd7f20a1e14b0e8a0d08338028065f8a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "The company attributed the guidance cut to a larger-than-expected shift in payer mix and a greater financial impact from health insurance exchanges.",
                "category": "company",
                "datetime": 1784043119,
                "headline": "HCA Stock Plummets After Slashing 2026 Guidance – Marks Fifth Straight Day Of Losses"
              },
              {
                "id": 140903881,
                "url": "https://finnhub.io/api/news?id=4a193f2e0488f271f259a27b32b77b0cd93c67049404d489714065015d5de8a8",
                "image": "",
                "source": "Benzinga",
                "related": "LLY",
                "summary": "https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-traditional-approval-selpercatinib-locally-advanced-or-metastatic-ret-fusion-positive",
                "category": "company",
                "datetime": 1784038889,
                "headline": "FDA Grants Approval For Eli Lilly's Selpercatinib For Patients With Locally Advanced Or Metastatic Solid Tumors With A RET Gene Fusion"
              },
              {
                "id": 140898041,
                "url": "https://finnhub.io/api/news?id=f81b5704db160b35b4aa4e9fe38b791120b54b59fe0684be4ae1b6f05f59f94e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "JNJ's 25% year-to-date surge and recent FDA approval fuel interest in healthcare ETFs with diversified sector exposure.",
                "category": "company",
                "datetime": 1784037240,
                "headline": "Healthcare ETFs to Buy as JNJ Beats the Market With a 25% YTD Surge"
              },
              {
                "id": 140896832,
                "url": "https://finnhub.io/api/news?id=cd7d8f48709f03cfb02a2c4fe33cae2ce945561754784b3a831991e3b9c5278f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "SAN FRANCISCO, July 14, 2026--Chai Discovery, the company engineering AI models to discover new molecules, today announced a $400M Series C fundraise to further accelerate progress.",
                "category": "company",
                "datetime": 1784034000,
                "headline": "Chai Discovery Announces $400M Series C to Advance AI-Driven Molecular Design"
              },
              {
                "id": 140903882,
                "url": "https://finnhub.io/api/news?id=c81b00d47be8eecf014e65f40cae832c952d731b362ed2dcb0222dccca3c8ab9",
                "image": "",
                "source": "Benzinga",
                "related": "LLY",
                "summary": "Bernstein  analyst Courtney Breen   maintains Eli Lilly (NYSE:LLY) with a Outperform and raises the price target from $1300 to $1385.",
                "category": "company",
                "datetime": 1784025542,
                "headline": "Bernstein Maintains Outperform on Eli Lilly, Raises Price Target to $1385"
              },
              {
                "id": 140895900,
                "url": "https://finnhub.io/api/news?id=c957d7aab767bbff736dd78fe1f3c966b7b1792093d60a3ffc342b4647afabbf",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Eyes are on the rollout of Lilly's new weight loss pill.",
                "category": "company",
                "datetime": 1784025000,
                "headline": "Is This Disturbing Trend Bad News for Eli Lilly in the Billion-Dollar Obesity Drug Market?"
              },
              {
                "id": 140895218,
                "url": "https://finnhub.io/api/news?id=ac09b1e825d85078efac14d5865d13b080a0223865d4193158494544f04990de",
                "image": "https://www.chartmill.com/images/uploads/thumbnail_article_navellier_3be8c6e05a.webp",
                "source": "ChartMill",
                "related": "LLY",
                "summary": "Louis Navellier’s eight-rule growth investing framework identifies stocks with strong earnings momentum and efficiency. Eli Lilly (LLY) passes this screen, showing exceptional sales, earnings, and cash flow growth.",
                "category": "company",
                "datetime": 1784022636,
                "headline": "Eli Lilly & Co. (NYSE:LLY) Passes Navellier’s High-Growth Screen on Strong Earnings and Sales Momentum"
              },
              {
                "id": 140893297,
                "url": "https://finnhub.io/api/news?id=7dfb55981816cba5173c9bfa6229bb73be2048d1ec30f80b16845c2bb2712d95",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Madrigal Pharmaceuticals announced earlier on Friday that it has received three new U.S. patents for its lead drug, Rezdiffra.",
                "category": "company",
                "datetime": 1783986466,
                "headline": "MDGL Stock In Focus — Retail Traders Buzz Over M&A Speculation And Fresh Patents For Liver Drug"
              },
              {
                "id": 140889976,
                "url": "https://finnhub.io/api/news?id=853634e3215adae0307c8aa5ba126a884c266f5f82638bd677c0b4bb959be1c4",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Eli Lilly has whipsawed shareholders in 2026, but one under-the-radar catalyst in its pipeline could change the trajectory entirely. Here is what the bulls are watching that most investors are still sleeping on.",
                "category": "company",
                "datetime": 1783965635,
                "headline": "Prediction: 1 New Reason Eli Lilly Stock Could Still Be Headed Higher"
              },
              {
                "id": 140888353,
                "url": "https://finnhub.io/api/news?id=4485315c448a89a6ae42a93ee1eff88cb436b1981d6da3cd995a10471ecdc57d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Cathie Wood Unveils Major Portfolio Reset With SpaceX, Meta Buys and AMD Cuts",
                "category": "company",
                "datetime": 1783961547,
                "headline": "Cathie Wood Loads Up on SpaceX, Meta, Eli Lilly and Circle Group"
              },
              {
                "id": 140890428,
                "url": "https://finnhub.io/api/news?id=19d739b4927a93cabbd2b4851d7ce4d2fd6f440ccf87508ea6d90be82d6ca59d",
                "image": "",
                "source": "Benzinga",
                "related": "LLY",
                "summary": "https://fingfx.thomsonreuters.com/gfx/legaldocs/jnpwzaojlvw/TEVA%20LILLY%20FORTEO%20LAWSUIT%207thcir.pdf",
                "category": "company",
                "datetime": 1783956607,
                "headline": "U.S. Appeals Court Revives Teva Pharmaceuticals' Lawsuit Against Eli Lilly Over Alleged Violation Of Settlement Agreement"
              },
              {
                "id": 140886796,
                "url": "https://finnhub.io/api/news?id=f9b778750087e7257dcaa89a698cc3abdd980ec775cf51eb75bfbabbca689d65",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Cathie Wood's ARK Invest was extremely active last week, adding SpaceX and Meta, while selling AMD and Robinhood stock.",
                "category": "company",
                "datetime": 1783954101,
                "headline": "Cathie Wood Bought $54 Million Worth Of SpaceX Stock Last Week"
              },
              {
                "id": 140892268,
                "url": "https://finnhub.io/api/news?id=8888a5803a2f00d091ba116f4ce07d087b72c3d912194a3c45b48d32214a6c29",
                "image": "",
                "source": "Benzinga",
                "related": "LLY",
                "summary": "UBS  analyst Michael Yee   maintains Eli Lilly (NYSE:LLY) with a Buy and raises the price target from $1250 to $1425.",
                "category": "company",
                "datetime": 1783952743,
                "headline": "UBS Maintains Buy on Eli Lilly, Raises Price Target to $1425"
              },
              {
                "id": 140885768,
                "url": "https://finnhub.io/api/news?id=beb87ad176efb9fdff630913987b4267d509627241251c66ccf0cea69cf5af22",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "At $1,189, Eli Lilly (LLY) looks set up for roughly 76% of upside over the next three years under a conservative scenario. That is a move large enough to justify digging into where it comes from. Revenue compounding does the work, but the multiple takes a meaningful cut along the way. Here is the operational reality the math is built on.",
                "category": "company",
                "datetime": 1783948326,
                "headline": "How Does LLY Stock Reach $2,100?"
              },
              {
                "id": 140884976,
                "url": "https://finnhub.io/api/news?id=528f6379fc7107f3ed28cd97001d1af154a02757ac72e99736c901f4f9a86c42",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "RICHMOND, Va., July 13, 2026--Capital Square, a leading sponsor of tax-advantaged real estate investments and a national developer and manager of housing communities, has fully subscribed CS1031 Richmond Active Living Apartments, DST, a Regulation D private placement offering that raised equity from 108 investors. The Delaware statutory trust holds a 165-unit, Class A, age-restricted multifamily community in the Short Pump suburb of Richmond, Virginia, near Capital Square’s headquarters.",
                "category": "company",
                "datetime": 1783940400,
                "headline": "Capital Square Fully Subscribes Richmond Active-Adult DST Offering"
              },
              {
                "id": 140892269,
                "url": "https://finnhub.io/api/news?id=67a50f94bc36f1f379bdaa11c0218a66643ef22ad54a7b101d03828308b2f40d",
                "image": "https://cdn.benzinga.com/files/images/story/2026/07/13/Eli-Lilly-Tax-Payments-Shift.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "LLY",
                "summary": "Eli Lilly shares are in the spotlight Monday as the company presents new Kisunla data at the AAIC in London.",
                "category": "company",
                "datetime": 1783932562,
                "headline": "Eli Lilly Stock in Focus as Company Presents New Kisunla Data at AAIC Following Wave of Analyst Upgrades"
              },
              {
                "id": 140884344,
                "url": "https://finnhub.io/api/news?id=4ceb91cd7becada7604bb3488ec60c7e743439b05e47c16231893ddc48558cbc",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Two drugs now generate almost two-thirds of the pharmaceutical giant's revenue.",
                "category": "company",
                "datetime": 1783932180,
                "headline": "Here's How Much Eli Lilly's Weight-Loss Drugs Are Worth to Investors"
              },
              {
                "id": 140892270,
                "url": "https://finnhub.io/api/news?id=5d503b25613f831bbf329175c1021d4821c28b0e8c30717ea3fc6eb9cea5d2fb",
                "image": "",
                "source": "Benzinga",
                "related": "LLY",
                "summary": "Guggenheim  analyst Seamus Fernandez   maintains Eli Lilly (NYSE:LLY) with a Buy and lowers the price target from $1235 to $1273.",
                "category": "company",
                "datetime": 1783931868,
                "headline": "Guggenheim Maintains Buy on Eli Lilly, Lowers Price Target to $1273"
              },
              {
                "id": 140883830,
                "url": "https://finnhub.io/api/news?id=10a857ac60fefead3fd586415331027da653fab64eb60679569e05a388e39fde",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "PARIS, July 13, 2026--Sofinnova Partners (\"Sofinnova\"), a leading European venture capital firm in life sciences, based in Paris, London, and Milan, announced the appointment of David Evans as Partner. A physician-scientist with deep pharma and drug development expertise, Evans joins from the Roche Venture Fund, where he most recently served as Senior Investment Director. His career spans frontline patient care as a doctor in Australia and with Médecins Sans Frontières, health policy and financi",
                "category": "company",
                "datetime": 1783922400,
                "headline": "Sofinnova Partners Appoints David Evans as Partner"
              },
              {
                "id": 140887884,
                "url": "https://finnhub.io/api/news?id=d6b97e5e2d0a0da4424ed28339ad0a3425ddba2d38f6891101f093022cabcc9c",
                "image": "https://cdn.benzinga.com/files/images/story/2026/07/13/Closeup-one-hundred-US-dollar-bills-unde.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "LLY",
                "summary": "HHS watchdog projected $5.56 billion in recoveries and savings over six months despite enforcement falling to a two-year low.",
                "category": "company",
                "datetime": 1783912149,
                "headline": "Federal Health Watchdog Projects $5.56 Billion in Recoveries and Savings, Despite Enforcement Hitting Two-Year Low"
              },
              {
                "id": 140871121,
                "url": "https://finnhub.io/api/news?id=5f2a2d16390b18a79e25fba4b67df2bdfcba26a350c96041ac7d34fa5a5f21ad",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "This is the list for you if you are looking for dividend stocks with attractive yields and well-supported dividends.",
                "category": "company",
                "datetime": 1783776900,
                "headline": "3 Dividend Stocks That Are No-Brainer Buys Heading Into the Second Half of 2026"
              },
              {
                "id": 140869911,
                "url": "https://finnhub.io/api/news?id=bcd8f15ebb03e3568bc541bfac55c5852ab3cd576eba6ef9d27eee8464f7e20b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "There are good reasons to invest in Lilly and to hold off.",
                "category": "company",
                "datetime": 1783760640,
                "headline": "Should You Buy Eli Lilly Stock? Here's My Honest Take."
              },
              {
                "id": 140868785,
                "url": "https://finnhub.io/api/news?id=1222dbd0e33abeb26678833c523058c9f542d2588c9d968ce5c8336f051c40b5",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Eli Lilly plans to present new Alzheimer's research at the 2026 Alzheimer's Association International Conference, including long term data on Kisunla (donanemab-azbt). The company will share updated safety and biomarker findings from its Kisunla program. Eli Lilly will also outline progress on blood based P-tau217 diagnostics that could support broader Alzheimer's screening. Eli Lilly, traded as NYSE:LLY, is set to bring fresh Alzheimer's data to the forefront, while attention has recently...",
                "category": "company",
                "datetime": 1783743328,
                "headline": "Eli Lilly (LLY) To Share New Kisunla And Alzheimer’s Blood Test Data At AAIC"
              },
              {
                "id": 140868961,
                "url": "https://finnhub.io/api/news?id=7c6dcedf16148bc616a2adf5030c7ad17be73914ef7a21ec565cd80def4de433",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1351962969/image_1351962969.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "LLY",
                "summary": "The “sell AI” trade that started in early summer has quietly grown a positive side, and that side is healthcare.",
                "category": "company",
                "datetime": 1783736700,
                "headline": "Macro Note: The Tech Unwind Grew A Second Leg, And It's Healthcare"
              },
              {
                "id": 140866922,
                "url": "https://finnhub.io/api/news?id=25d7acb47f3ed9eca0886a9f0080884afee31f93b3c3913488146df9acb10ba7",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "So far, Pfizer has been an also-ran in the GLP-1 race, but that could change if its long-acting weight-loss medication takes off.",
                "category": "company",
                "datetime": 1783726500,
                "headline": "Is Pfizer on Track to Launch Its Next Lipitor -- This Time in the Weight-Loss Market?"
              },
              {
                "id": 140864232,
                "url": "https://finnhub.io/api/news?id=91a02918a5278124662a610b3899e8198d2c7971f595e01efcfbf99480df0d7a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Moderna, ImmunityBio, and Sarepta are all cratering today despite bullish recent news and no negative catalysts in sight, leaving investors scrambling to understand whether the biotech sector's monster 2026 run has finally hit a wall.",
                "category": "company",
                "datetime": 1783699478,
                "headline": "Moderna Drops 11%, ImmunityBio and Sarepta Therapeutics Tumble 8% in Biotech Rout"
              },
              {
                "id": 140862896,
                "url": "https://finnhub.io/api/news?id=0c301d7f2b398dc00ad7c779c5814ef6ecc68d67de60e9199a241944cb2c21bd",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Novo Nordisk stock gains 11% in a month as Wegovy access expands and U.K. approval boosts optimism, but rising competition and earnings pressure cloud the outlook.",
                "category": "company",
                "datetime": 1783692660,
                "headline": "NVO Rallies 11% in a Month: How Should Investors Play the Stock?"
              },
              {
                "id": 140866545,
                "url": "https://finnhub.io/api/news?id=9cc45cae68dafe8692fc093002acadbb7de1fd69729bca9b60e6ed9154568cb3",
                "image": "",
                "source": "Benzinga",
                "related": "LLY",
                "summary": "B of A Securities  analyst Jason Gerberry   maintains Eli Lilly (NYSE:LLY) with a Buy and raises the price target from $1251 to $1334.",
                "category": "company",
                "datetime": 1783692345,
                "headline": "B of A Securities Maintains Buy on Eli Lilly, Raises Price Target to $1334"
              },
              {
                "id": 140864871,
                "url": "https://finnhub.io/api/news?id=0b230cf4ef13909094f0c290b905986804d9f285937fd22e25e8cdfb17957867",
                "image": "https://cdn.benzinga.com/files/images/story/2025/11/06/aggregated_options_1.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "LLY",
                "summary": "This whale alert can help traders discover the next big trading opportunities.\nWhales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.\nTraders will",
                "category": "company",
                "datetime": 1783690507,
                "headline": "6 Health Care Stocks With Whale Alerts In Today’s Session"
              },
              {
                "id": 140861555,
                "url": "https://finnhub.io/api/news?id=fe0097a1d1dc84c557427a69c3a73840d1ee31881d8fde66985a82b7b6aaa9cb",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "This healthcare giant is on a serious run, but for investors arriving now, the question is whether the price of admission already includes the victory lap.",
                "category": "company",
                "datetime": 1783684953,
                "headline": "JNJ Stock Keeps Climbing. Should You Climb On?"
              },
              {
                "id": 140860646,
                "url": "https://finnhub.io/api/news?id=a5275756f88fc3a60e681d21dbc3afb05ca02eb4d3c2800251dc78113098a910",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "In the latest monthly list of new buys by the best mutual funds, top money managers aggressively scooped up shares of 19 stocks, including Eli Lilly, GE Aerospace, Taiwan Semiconductor Manufacturing and CrowdStrike.",
                "category": "company",
                "datetime": 1783682566,
                "headline": "Top Funds Bet Big On 19 Stocks — Including Eye-Popping Sums On These Five"
              },
              {
                "id": 140859133,
                "url": "https://finnhub.io/api/news?id=f3b3f970a75ff80e094b724eb87270ab4f26b82709f3ffaea915396f145b4708",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Biotech is gaining momentum as healthcare leads higher, with several drugmakers and life sciences companies showing improving earnings trends and breakouts.",
                "category": "company",
                "datetime": 1783665420,
                "headline": "Zacks Investment Ideas feature highlights: XLV, XBI, LLY, EXEL, PTCT, FTRE and ILMN"
              },
              {
                "id": 140855712,
                "url": "https://finnhub.io/api/news?id=6cc6c5f38488037e60e08c1d2aae9752974b3b3dc318b6fd86f9fde0597446d1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Eli Lilly makes the best-selling GLP-1 drug, and sales are accelerating.",
                "category": "company",
                "datetime": 1783627020,
                "headline": "Record Numbers of Americans Are on GLP-1 Drugs. That's Great News for This Stock."
              },
              {
                "id": 140854672,
                "url": "https://finnhub.io/api/news?id=5ab5bb83d308f4e877be54702b0f4785329be7a884587e842d83b5218288e07e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Roughly $400 billion. That is how much market value Eli Lilly (NYSE:LLY) has added over the past year, with shares climbing from $773.86 on July 2, 2025 to $1,213.91 on July 2, 2026, a 56.86% gain that has pushed the drugmaker’s market capitalization to $1.063 trillion. No other Big Pharma name has expanded its footprint ... Eli Lilly’s $400 Billion Surge Is Reshaping Big Pharma",
                "category": "company",
                "datetime": 1783621688,
                "headline": "Eli Lilly’s $400 Billion Surge Is Reshaping Big Pharma"
              },
              {
                "id": 140853483,
                "url": "https://finnhub.io/api/news?id=7f0f6609f05d4b5757e92a3c0ee70a033a95ba8a1b7a350b1878bc4ebde3b566",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Eli Lilly and Company (NYSE: LLY) today announced it will present 16 abstracts at the 2026 Alzheimer's Association International Conference (AAIC), July 12-15 in London. Three oral presentations anchor the scientific program, with 13 poster presentations spanning imaging science, health economics, real-world prescribing evidence, and patient-centered outcomes, reflecting Lilly's 35-year commitment to answering open questions in Alzheimer's disease.",
                "category": "company",
                "datetime": 1783617360,
                "headline": "/C O R R E C T I O N -- Eli Lilly and Company/"
              },
              {
                "id": 140854673,
                "url": "https://finnhub.io/api/news?id=29953f580c8a9fc3d5c94760a243e5576cfbd9633038a5409e6067a2a5fd63fa",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Biotechnology stocks like Illumina, Eli Lilly and Exelixis have quietly turned into the new market leaders.",
                "category": "company",
                "datetime": 1783616640,
                "headline": "Stocks Look Shaky, But This Sector is Booming (Biotech)"
              },
              {
                "id": 140853484,
                "url": "https://finnhub.io/api/news?id=a37245c725bdaa7038adeca694577bae64e2a1096e408d1811dd4be0d93626e9",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "The Health Care Select Sector SPDR Fund (NYSEARCA:XLV) is the default healthcare allocation for millions of investors, and for good reason. XLV owns the entire S&P 500 healthcare complex in one ticker: insurers, device makers, biotech, and Big Pharma. It has returned 21.61% over the past year and 159.84% over ten years. If the reason ... Two Drugmakers Own 90% of the Obesity Boom. One Fund Owns Both for 0.59%",
                "category": "company",
                "datetime": 1783613908,
                "headline": "Two Drugmakers Own 90% of the Obesity Boom. One Fund Owns Both for 0.59%"
              },
              {
                "id": 140852010,
                "url": "https://finnhub.io/api/news?id=553e10dc88f8db461878d38f0666f117101c8f854c6a22e5273fb7ce1784b80d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "CNBC’s Jim Cramer pushed viewers away from the usual semiconductor and hyperscaler chatter. Instead, he highlighted a group he says has quietly become the market’s leader. “There is a move in biotech that we have not talked about at all that is really extraordinary, and particularly since the change at the head of the FDA,” ... Jim Cramer Says Biotech is The Hottest Group in The Market Right Now",
                "category": "company",
                "datetime": 1783611325,
                "headline": "Jim Cramer Says Biotech is The Hottest Group in The Market Right Now"
              },
              {
                "id": 140852114,
                "url": "https://finnhub.io/api/news?id=18cb1deec87714a810815bec92145326d36f86f537c4507db6c6fe56c1ba3f15",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Viking Therapeutics' expanding obesity pipeline and upcoming VK2735 data reignite buyout speculation as investors weigh its growing strategic appeal.",
                "category": "company",
                "datetime": 1783605360,
                "headline": "Buyout Buzz Around VKTX Is Back: What's Fueling the Speculation?"
              },
              {
                "id": 140854329,
                "url": "https://finnhub.io/api/news?id=f85d59ff5cf636e53f4a04b2a9899cbee55215709e026bf0dbff25839923e5cd",
                "image": "https://cdn.benzinga.com/files/images/story/2025/11/06/aggregated_options_3.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "LLY",
                "summary": "This whale alert can help traders discover the next big trading opportunities.\nWhales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.\nTraders often",
                "category": "company",
                "datetime": 1783604108,
                "headline": "9 Health Care Stocks With Whale Alerts In Today’s Session"
              },
              {
                "id": 140850812,
                "url": "https://finnhub.io/api/news?id=276e65ac7c5991a39aa9ec7a3758acb5f3ce4bad2e75fab780b4fe5f46f7d0c9",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "AbbVie's stock commands a king's ransom, but its performance metrics rule the kingdom, leaving investors to ask if they are buying at the top of the reign.",
                "category": "company",
                "datetime": 1783602824,
                "headline": "ABBV Leads Its Peer Group. You Pay For That"
              },
              {
                "id": 140850813,
                "url": "https://finnhub.io/api/news?id=50fe695c6a36d08d65a0a18fef1e35d803ac85b36d09df2ce807f7b82ab5f756",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Eli Lilly Wins Positive Canada Recommendation, Strengthening Drug Pipeline",
                "category": "company",
                "datetime": 1783601052,
                "headline": "Eli Lilly Stock Gets a Lift After Canada Backs Eczema Drug"
              },
              {
                "id": 140850814,
                "url": "https://finnhub.io/api/news?id=05ce077906bfc530a482322e629b82e62aeb3e9fbbbbcf058e73d19af507c405",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Ebglyss received a positive recommendation that could expand public access.",
                "category": "company",
                "datetime": 1783599912,
                "headline": "Lilly Gets Canada Boost"
              },
              {
                "id": 140850815,
                "url": "https://finnhub.io/api/news?id=5be54a290529b9ace35b284e57b9ef50d322b5dd549d35120402b2d467a67c2e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "The GLP-1 trade has matured from a single-stock story into a tiered opportunity set. Demand for obesity therapeutics keeps expanding as lower-cost, easier-to-administer oral pill versions of the current injectable GLP-1s are introduced to the market in 2026, and the field now spans an entrenched leader, a deep-value incumbent, and a clinical-stage challenger with multiple ... 3 High Growth GLP-1 Biotech Winners to Buy in July",
                "category": "company",
                "datetime": 1783598459,
                "headline": "3 High Growth GLP-1 Biotech Winners to Buy in July"
              },
              {
                "id": 140849930,
                "url": "https://finnhub.io/api/news?id=ab384ad81929c67c34b3717b8f7b67d75591d4ca1323592f9ffb152c69fe419d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Eli Lilly and Company (NYSE: LLY) today announced it will present 16 abstracts at the 2026 Alzheimer's Association International Conference (AAIC), July 12-15 in London. Three oral presentations anchor the scientific program, with 13 poster presentations spanning imaging science, health economics, real-world prescribing evidence, and patient-centered outcomes, reflecting Lilly's 35-year commitment to answering open questions in Alzheimer's disease.",
                "category": "company",
                "datetime": 1783596600,
                "headline": "Lilly to present Alzheimer's disease diagnostic and therapeutic research at AAIC 2026, including new data on P-tau217 blood tests and amyloid-targeting treatment"
              },
              {
                "id": 140849314,
                "url": "https://finnhub.io/api/news?id=6a15b324766510145d17f59f727aa252b28f2333585268ec5933f21185148209",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Wall Street’s bearish price targets for the stocks in this article signal serious concerns. Such forecasts are uncommon in an industry where maintaining cordial corporate relationships often trumps delivering the hard truth.",
                "category": "company",
                "datetime": 1783587660,
                "headline": "1 Unpopular Stock That Should Get More Attention and 2 That Underwhelm"
              },
              {
                "id": 140850358,
                "url": "https://finnhub.io/api/news?id=840cbddb211ad3a61dbdba03223eb2cf874f8da5b0b48f025699b494ac5f7406",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2256411028/image_2256411028.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "LLY",
                "summary": "Novo Nordisk regains competitive ground in obesity with the strong launch of the Wegovy pill, reversing some of the recent underperformance against Eli Lilly.",
                "category": "company",
                "datetime": 1783586769,
                "headline": "Novo Nordisk's Wegovy Pill Escalates Eli Lilly Rivalry"
              },
              {
                "id": 140849876,
                "url": "https://finnhub.io/api/news?id=7b8e8d675dfac6652eca3629f3e77e99cd7ed41fe81802606ce648a484403674",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2153927815/image_2153927815.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "LLY",
                "summary": "Novo Nordisk (NVO) rated Buy as catalysts support the bull case despite a pullback; strong outperformance and anti-AI diversification.",
                "category": "company",
                "datetime": 1783583531,
                "headline": "Novo Nordisk: Why I Don't Think The Story Is Broken"
              },
              {
                "id": 140851449,
                "url": "https://finnhub.io/api/news?id=573a6639a8a96b81c5c110420a86ccf128877895b974511e7c25eeef0379d50c",
                "image": "",
                "source": "Benzinga",
                "related": "LLY",
                "summary": "Analyses across Kisunla (donanemab-azbt) trials providing further insights into the benefit-risk profile from long-term extension dataNew data compares the diagnostic performance of P-tau217 blood tests with amyloid",
                "category": "company",
                "datetime": 1783582595,
                "headline": "Eli Lilly Highlights Alzheimer’s Research With 16 Abstracts At AAIC 2026, Including Three Oral Presentations"
              },
              {
                "id": 140848108,
                "url": "https://finnhub.io/api/news?id=83802d7c0c6cf8398ae3af9cf033877b0a4aec73cbd5ee80e3f87882e6d45d45",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Eli Lilly (LLY) keeps setting records, and Wall Street’s rating of its stock keeps increasing as well. On Tuesday, one of JPMorgan’s most closely watched healthcare stock analysts, Chris Schott, who frequently covers Pfizer Inc. (PFE), Eli Lilly, and Teva Pharmaceutical Industries Ltd. ...",
                "category": "company",
                "datetime": 1783573620,
                "headline": "JPMorgan resets LLY stock target on drug demand"
              },
              {
                "id": 140847554,
                "url": "https://finnhub.io/api/news?id=1baa1b4621c667c7dd7cbc7799844be0120b8a10a4eabc7b18fd7c43594c950b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "In late June 2026, Innovent Biologics announced a distribution and promotion agreement giving it sole commercialization rights for Eli Lilly’s breast cancer drug Verzenios in mainland China, while Lilly retains manufacturing, supply and development responsibilities. At the same time, Eli Lilly received a positive regulatory opinion in Europe for expanding Jaypirca’s use in chronic lymphocytic leukemia, underscoring how partnerships and oncology approvals are broadening the company’s reach...",
                "category": "company",
                "datetime": 1783563131,
                "headline": "Innovent’s China Verzenios Deal and New Jaypirca Nod Might Change The Case For Investing In Eli Lilly (LLY)"
              },
              {
                "id": 140844429,
                "url": "https://finnhub.io/api/news?id=dd7d7d9ca5fb3ceacc06fc041a1ce8619df249d6a7c47408bf87031bac38c4fa",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Healthcare stocks were lower late Wednesday afternoon, with the NYSE Healthcare Index down 0.9% and",
                "category": "company",
                "datetime": 1783539672,
                "headline": "Sector Update: Healthcare Stocks Decline Late Afternoon"
              },
              {
                "id": 140844401,
                "url": "https://finnhub.io/api/news?id=1e6f7b15e160167e71834984cc3c9da524bf2f444e60c4777d8c0607565d09f4",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "The chipmaker signaled a major turn in its business, and the market bought it. Now comes the hard part: proving the rally can last.",
                "category": "company",
                "datetime": 1783535858,
                "headline": "Texas Instruments Stock Is Running On A Bold Promise"
              },
              {
                "id": 140844431,
                "url": "https://finnhub.io/api/news?id=517289ea385ef94a54e96d252953d062a70f0279f2fc7da75685a75a2439106e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "The stock has soared 400% in recent years.",
                "category": "company",
                "datetime": 1783535400,
                "headline": "Is It Too Late to Buy Eli Lilly?"
              },
              {
                "id": 140844432,
                "url": "https://finnhub.io/api/news?id=cd199b5810e0e84a3259104047b7c8886fe8b81f7e81e9a39ba5669e58e76089",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Check out the companies making headlines yesterday:",
                "category": "company",
                "datetime": 1783534244,
                "headline": "Stocks making big moves yesterday: Carlisle, Rivian, Blink Charging, Genpact, and Eli Lilly"
              },
              {
                "id": 140843361,
                "url": "https://finnhub.io/api/news?id=23a83b0f79f0aeec1462c7635da85a068595f3d6b54a7056a899147ef66df2ea",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Healthcare stocks declined Wednesday afternoon, with the NYSE Healthcare Index and the State Street",
                "category": "company",
                "datetime": 1783532895,
                "headline": "Sector Update: Healthcare Stocks Lower Wednesday Afternoon"
              },
              {
                "id": 140843362,
                "url": "https://finnhub.io/api/news?id=597f4902dfd05c08eeacaf56c3d2203bd898010321778f32442a1e1312d5a219",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Major US biopharmaceutical companies' performance in the second half of the year is likely to be dri",
                "category": "company",
                "datetime": 1783529860,
                "headline": "Biopharma Companies' Second-Half Performance to be Largely Driven by Fundamentals, Morgan Stanley Says"
              },
              {
                "id": 140851450,
                "url": "https://finnhub.io/api/news?id=464ecfb36d2a5d496fc9243ee13f6fa0b475853aecd3ac02a98e9d531d9a0ddd",
                "image": "",
                "source": "Benzinga",
                "related": "LLY",
                "summary": "Estimated Second Quarter 2026 Acquired In-Process Research and Development ("IPR&D") Charges Eli Lilly and Company ("Lilly") currently expects that its reported financial results calculated in",
                "category": "company",
                "datetime": 1783528576,
                "headline": "Eli Lilly Estimates $2.8B Q2 2026 Acquired IPR&D Charges, Impacting GAAP And Non-GAAP EPS By ~$3.02 Per Share"
              },
              {
                "id": 140853485,
                "url": "https://finnhub.io/api/news?id=7b86bbff6fb3fc6485d7790cc61a4572282dd3e8f99f0b1c923747f3f413dee6",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "As Middle East tensions resurface and futures drop, VIG, VIGI, and FDVV offer dividend growth ETFs combining income with exposure to technology and global equities.",
                "category": "company",
                "datetime": 1783528500,
                "headline": "The Market Just Got Shaken—These 3 ETFs May Come Out Stronger"
              },
              {
                "id": 140843363,
                "url": "https://finnhub.io/api/news?id=ac1f7856ad14fbc526e0ef6181738c057cb8a26abf9b6b6c96af0a17c37867bc",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "The pharmaceutical industry is entering a new era where biology and artificial intelligence are converging. Drug discovery, once a slow process measured in years and billions of dollars, is increasingly becoming a data-driven competition. Companies that combine proprietary medical data with AI tools may gain an advantage similar to what technology companies achieved during the ... Wall Street Is Betting on Eli Lilly’s GLP-1 Portfolio — It’s Missing the $1 Trillion Opportunity",
                "category": "company",
                "datetime": 1783526572,
                "headline": "Wall Street Is Betting on Eli Lilly’s GLP-1 Portfolio — It’s Missing the $1 Trillion Opportunity"
              },
              {
                "id": 140841778,
                "url": "https://finnhub.io/api/news?id=c1d9e054f88af7cc76ad45c92c50beba49c8aebc5a78167930dc9e5fb87ef4c1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "For shareholders, the coming year isn't about a small gain or loss but a potential journey to one of two very different destinations.",
                "category": "company",
                "datetime": 1783524984,
                "headline": "The Wide Divide Ahead For Eli Lilly Stock"
              },
              {
                "id": 140844286,
                "url": "https://finnhub.io/api/news?id=96388c85ef3321ec419afc0d68f7d6bbe86334c1db1eb5e8c1f9074e9370c9c1",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2280004284/image_2280004284.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "LLY",
                "summary": "Schrödinger is a Hold, reflecting both its strategic potential and the high-risk, hit-or-miss nature of AI-driven drug discovery. Read more on SDGR stock here.",
                "category": "company",
                "datetime": 1783524866,
                "headline": "Schrödinger: Surviving, If Not Thriving, In The Tricky AI Drug Discovery Field"
              },
              {
                "id": 140841648,
                "url": "https://finnhub.io/api/news?id=4802d2ffd0cc0a211b58bbc1846e380f92f5daea9f6bb335ed4c2df9ba30177e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Eli Lilly (LLY) is expected to deliver Q2 revenue slightly above consensus on stronger-than-anticipa",
                "category": "company",
                "datetime": 1783524815,
                "headline": "Eli Lilly Expected to Beat Q2 Revenue Forecasts on Weight-Loss Drugs, RBC Says"
              },
              {
                "id": 140841649,
                "url": "https://finnhub.io/api/news?id=46cf1067762772bdaff0bf3cd43eb85b6816d116b9c6119f06b2aaa77d698dba",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Biopharma sector's performance in H2 is expected to be driven more by company fundamentals rather th",
                "category": "company",
                "datetime": 1783523510,
                "headline": "Biopharma Sector Seen Shifting to Fundamentals From Macro in H2, Morgan Stanley Says"
              },
              {
                "id": 140841650,
                "url": "https://finnhub.io/api/news?id=526e951a446178bff7233b2556495f0ced7d476d080f218fd7f9923c9cdaf739",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Eli Lilly (LLY) is poised to outpace second-quarter sales consensus estimates as strong volume uptak",
                "category": "company",
                "datetime": 1783523167,
                "headline": "Eli Lilly Weight-Loss, Diabetes Franchise to Drive Second Quarter Sales Beat, RBC Says"
              },
              {
                "id": 140841651,
                "url": "https://finnhub.io/api/news?id=455703245371c6ad44e673f88db76997b621b3dd38a629c2bb95b95103a45730",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Eli Lilly hits another record high as confidence grows in its obesity and diabetes portfolio, with Wall Street still seeing upside despite the rich valuation.",
                "category": "company",
                "datetime": 1783519800,
                "headline": "LLY Hits Another Record High: Is the Stock Too Expensive to Buy Now?"
              },
              {
                "id": 140853203,
                "url": "https://finnhub.io/api/news?id=cd79bc33512abc2a735e65d0de5a0445a51d2b2210e7df8dae0a272af1adbec7",
                "image": "https://image.cnbcfm.com/api/v1/image/108332252-17835317791783531776-47038724915-1080pnbcnews.jpg?v=1783531778&w=1920&h=1080",
                "source": "CNBC",
                "related": "LLY",
                "summary": "Michael Yee, UBS biotech analyst, joins 'The Exchange' to discuss Yee's thoughts on biotech stocks, what's driving the dealmaking cycle and much more.",
                "category": "company",
                "datetime": 1783517749,
                "headline": "Dealmaking in biotech sector has brought an extreme technical breakout, says UBS' Michael Yee"
              },
              {
                "id": 140845008,
                "url": "https://finnhub.io/api/news?id=4a277941766a5de0378493dafe626ec2f71fa68672a90db59eec27da35febbda",
                "image": "https://cdn.benzinga.com/files/images/story/2025/11/06/aggregated_options_1.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "LLY",
                "summary": "This whale alert can help traders discover the next big trading opportunities.\nWhales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.\nTraders will",
                "category": "company",
                "datetime": 1783517708,
                "headline": "9 Health Care Stocks Whale Activity In Today’s Session"
              },
              {
                "id": 140851452,
                "url": "https://finnhub.io/api/news?id=6184952ce7ef03ff836bef72014e16b373843a180d3181515a91279adff53860",
                "image": "",
                "source": "Benzinga",
                "related": "LLY",
                "summary": "Truist Securities  analyst Robyn Karnauskas   maintains Eli Lilly (NYSE:LLY) with a Buy and raises the price target from $1281 to $1370.",
                "category": "company",
                "datetime": 1783517657,
                "headline": "Truist Securities Maintains Buy on Eli Lilly, Raises Price Target to $1370"
              },
              {
                "id": 140840457,
                "url": "https://finnhub.io/api/news?id=9e72c27c012fca9943bec04714e89de7c0b215adec4f79eabf1bcfd6cc0e5dae",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Eli Lilly's next leg of growth may have less to do with how well its weight loss drugs work and more to do with how many people can finally get them.",
                "category": "company",
                "datetime": 1783515000,
                "headline": "Prediction: Eli Lilly Stock Will Hit This Price by the End of 2026"
              },
              {
                "id": 140851453,
                "url": "https://finnhub.io/api/news?id=fdaad7e4544d2d2994725e0f46a8cfa3f88b87474fb2bf84b97b77e5429174b8",
                "image": "",
                "source": "Benzinga",
                "related": "LLY",
                "summary": "Morgan Stanley  analyst Terence Flynn   maintains Eli Lilly (NYSE:LLY) with a Overweight and raises the price target from $1344 to $1347.",
                "category": "company",
                "datetime": 1783514754,
                "headline": "Morgan Stanley Maintains Overweight on Eli Lilly, Raises Price Target to $1347"
              },
              {
                "id": 140840458,
                "url": "https://finnhub.io/api/news?id=36aea8fb472977f6ec7345c9cc1edd40f494c1fd849d5a91c69b803aefbe9ddd",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "The Number $8.662 billion. That is what Mounjaro alone generated for Eli Lilly (NYSE:LLY) in the first quarter of 2026, a single product, a single quarter, up 125% year over year. The figure was disclosed in Lilly’s Q1 2026 earnings release on April 30, 2026, an actual reported figure. This key growth driver is what ... This $1,200 Stock Could Be the Next Massive Stock Split Opportunity",
                "category": "company",
                "datetime": 1783514550,
                "headline": "This $1,200 Stock Could Be the Next Massive Stock Split Opportunity"
              },
              {
                "id": 140840450,
                "url": "https://finnhub.io/api/news?id=8348267945daa038c90aa171f1d2b40e0f88bffbe8286fb277322272db70f3fe",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Dow Jones futures tumbled as President Donald Trump said the U.S.-Iran ceasefire is \"over.\" Crude oil prices soared.",
                "category": "company",
                "datetime": 1783512606,
                "headline": "Dow Jones Futures Fall, Oil Prices Soar As Trump Says U.S.-Iran Ceasefire 'Over'"
              },
              {
                "id": 140839574,
                "url": "https://finnhub.io/api/news?id=7698674c049960dc030e791f1b8be7bb515c6e751d6d139b93cda4800507af86",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Dow Jones futures tumbled as President Donald Trump said the U.S.-Iran ceasefire is \"over.\" Crude oil prices soared.",
                "category": "company",
                "datetime": 1783511815,
                "headline": "Dow Jones Futures Tumble, Oil Prices Soar As Trump Says U.S.-Iran Ceasefire 'Over'"
              },
              {
                "id": 140839627,
                "url": "https://finnhub.io/api/news?id=fbee3361fe35b0f98ea4c055b5e21cb28fa43ee3182cdb0d1dc5b297c6401170",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "A barrage of stocks to watch like Eli Lilly and Deere, show promise, alongside reminders to keep risk management in mind.",
                "category": "company",
                "datetime": 1783511458,
                "headline": "Stocks To Watch: 14 Names Test And Tease New Buy Zones"
              },
              {
                "id": 140841375,
                "url": "https://finnhub.io/api/news?id=df3a0d720bb3094397ee297dcaeaf94caeded699fd93e486e204391cf5f5f9a8",
                "image": "",
                "source": "Benzinga",
                "related": "LLY",
                "summary": "RBC Capital  analyst Trung Huynh   maintains Eli Lilly (NYSE:LLY) with a Outperform and raises the price target from $1250 to $1500.",
                "category": "company",
                "datetime": 1783504024,
                "headline": "RBC Capital Maintains Outperform on Eli Lilly, Raises Price Target to $1500"
              },
              {
                "id": 140842697,
                "url": "https://finnhub.io/api/news?id=1a296515cfd3e70e09644dd7937728f2304615e81013d3710a6b4c0c72ca4482",
                "image": "https://image.cnbcfm.com/api/v1/image/108328219-1782751789876-gettyimages-2279484892-64393_48_ms_4772.jpeg?v=1782751835&w=1920&h=1080",
                "source": "CNBC",
                "related": "LLY",
                "summary": "Around 36% of employers said they provide coverage of GLP-1s for both diabetes and weight loss, the same as 2025 and up from 34% in 2024, the survey said. ",
                "category": "company",
                "datetime": 1783502166,
                "headline": "Healthy Returns: Employers aren't expanding coverage of GLP-1 obesity drugs – many are finding ways around it"
              },
              {
                "id": 140839472,
                "url": "https://finnhub.io/api/news?id=dd881bcabc2bb19487918ffbc9709eff68916225493c5faeff1ce53c02d8bc5e",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2220524615/image_2220524615.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "LLY",
                "summary": "I track a curated universe of 50 high-quality dividend growth stocks to identify opportune entry points based on valuation and future return potential.",
                "category": "company",
                "datetime": 1783496560,
                "headline": "Top 50 High-Quality Dividend Growth Stocks For July 2026"
              },
              {
                "id": 140837473,
                "url": "https://finnhub.io/api/news?id=fc165123b8f5c5e56d10a592305f6c60639b04a3d8419f0acb89ef15cfa8bd4b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Wall Street is getting more bullish on the pharma giant's shares.",
                "category": "company",
                "datetime": 1783476817,
                "headline": "Why Eli Lilly Stock Climbed to a Record High Today"
              },
              {
                "id": 140836445,
                "url": "https://finnhub.io/api/news?id=1032e8869f60704f265d34943f045fc5216fefb4a5cd1e1f3128182b72910e4e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "The Nasdaq led the stock market lower Tuesday, as Samsung earnings slammed AI names. Oil prices jumped on U.S.-Iran news.",
                "category": "company",
                "datetime": 1783467920,
                "headline": "Dow Jones Futures: Oil Prices Keep Rising On Iran News After Samsung Fans AI Fears"
              },
              {
                "id": 140837887,
                "url": "https://finnhub.io/api/news?id=a2585bd314bcb6537e371bd1bc2a4946b73b2782ed389b67eb50f24a7e984265",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "While one continues reinvesting for growth, the other has rewarded shareholders for 54 years in a row.",
                "category": "company",
                "datetime": 1783467002,
                "headline": "AbbVie vs Eli Lilly: 1 Is Clearly the Better Dividend Stock to Buy and Hold for the Next 10 Years"
              },
              {
                "id": 140835334,
                "url": "https://finnhub.io/api/news?id=bd1040ad78b4ba83c41404d543c505aa24d8b557ebf9f66fdf37f149c144460e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "The Nasdaq led the stock market lower Tuesday, as Samsung earnings slammed AI names. Oil prices jumped on U.S.-Iran news.",
                "category": "company",
                "datetime": 1783461141,
                "headline": "Dow Jones Futures: Nasdaq Slumps As Samsung Fans AI Fears, Oil Prices Jump On Iran News"
              },
              {
                "id": 140835347,
                "url": "https://finnhub.io/api/news?id=7c2ba7baa099679035fad5170d750e7121c1446d52ed53d54af19195f6b4a2f1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Don't sleep on these medical device leaders.",
                "category": "company",
                "datetime": 1783461000,
                "headline": "Eli Lilly and Novo Nordisk Are Fine -- but These 2 Stocks Could Be an Even Better Way to Invest in the GLP-1 Boom"
              },
              {
                "id": 140835348,
                "url": "https://finnhub.io/api/news?id=a68c3d66200725b6473b4584c3bc6f68298be95f9834ad53e0ac6f61645c3d46",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) jumped 2.8% in the afternoon session after JPMorgan's Chris Schott raised his price target to $1,400 from $1,300, reiterating an Overweight rating.",
                "category": "company",
                "datetime": 1783459792,
                "headline": "Why Eli Lilly (LLY) Stock Is Trading Up Today"
              },
              {
                "id": 140835349,
                "url": "https://finnhub.io/api/news?id=932035aea36b61000d4c1bf7e2ad6926ed1243d7766729c37fe7af450e5e291d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Eli Lilly (LLY) is back in focus after handing Chinese partner Innovent Biologics full commercial control of breast cancer drug Verzenios, a shift that raises fresh questions about how the stock’s premium valuation stacks up. See our latest analysis for Eli Lilly. Verzenios is only one piece of a much bigger story for Eli Lilly. The stock gave back some ground in the latest session as the share price fell 1.14% to US$1,200.06, yet it is still showing firm momentum with a 30 day share price...",
                "category": "company",
                "datetime": 1783459022,
                "headline": "Eli Lilly (LLY) After The China Verzenios Shift And The Valuation Debate"
              },
              {
                "id": 140835338,
                "url": "https://finnhub.io/api/news?id=94b905cd04ca6b79a67ba855f8e46511577233b1c5fbd2891b5cc25d77cf31df",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Stock Market Today: The Nasdaq falls. IBM stock is a big Dow Jones index winner. Micron and Lam Research sell-off.",
                "category": "company",
                "datetime": 1783456555,
                "headline": "Stock Market Today: Nasdaq Is Day's Biggest Loser; Sandisk, Micron Tumble, Eli Lilly Shines"
              },
              {
                "id": 140835351,
                "url": "https://finnhub.io/api/news?id=260d72247d9f70efd510e08c54abe96362e0ed8be882639886d666c621748268",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "The stock is down, but it isn't out yet.",
                "category": "company",
                "datetime": 1783455600,
                "headline": "3 Reasons to Buy Novo Nordisk Stock"
              },
              {
                "id": 140835352,
                "url": "https://finnhub.io/api/news?id=cde7c44a0e7ab15b40a678d6dc96c3f9be5c0f283a2690eb28957cfa2f295b37",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Healthcare stocks were higher late Tuesday afternoon, with the NYSE Healthcare Index and the State S",
                "category": "company",
                "datetime": 1783453906,
                "headline": "Sector Update: Healthcare Stocks Gain Late Afternoon"
              },
              {
                "id": 140835353,
                "url": "https://finnhub.io/api/news?id=c4f382b5352bbe5ca224d50764aeb31d6d4bba886603869762d997d1bc75054d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Construction at  Pfizer’s  former headquarters in Manhattan was halted Tuesday because of crumbling floors and other structural issues.  The problems with the building’s renovation, which the company sold about eight years ago for conversion to apartments, are a metaphor of sorts for Pfizer stock, which began Tuesday with the highest yield in the  index, at more than 7%.  Pfizer stock, which is up 1.6% to $24.10 Tuesday, has been the worst performer among its large-cap U.S. peers during 2026 and over the past 10 years.",
                "category": "company",
                "datetime": 1783452120,
                "headline": "Former Pfizer Building Is Crumbling—Just as the Stock Has"
              },
              {
                "id": 140834188,
                "url": "https://finnhub.io/api/news?id=348634c830c438627985655c14385ec6bba641b5b23f9982edb7893e2b40441c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Drug stocks got hit hard on Monday in what Jim Cramer called a “vicious rotation,” and the selloff looked like the usual crowded-trade unwind. Investors decided the Mounjaro story was played out. On Tuesday morning’s Mad Dash, Cramer walked through why he thinks that reading is wrong, and he had a fresh JPMorgan note flagging ... Everyone Thinks the Eli Lilly Story Is Played Out. Cramer Thinks They’re Dead Wrong",
                "category": "company",
                "datetime": 1783450513,
                "headline": "Everyone Thinks the Eli Lilly Story Is Played Out. Cramer Thinks They’re Dead Wrong"
              },
              {
                "id": 140834189,
                "url": "https://finnhub.io/api/news?id=720d1fcb511546fccf6918a9df0be6c8000abd30049807e1f14940c8e6c06704",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Good medical care will always be in high demand, which makes some healthcare stocks strong long-term picks.",
                "category": "company",
                "datetime": 1783449300,
                "headline": "U.S. Healthcare Spending Just Hit $5.7 Trillion and Continues to Grow: 2 Stocks to Buy to Profit From the Trend"
              },
              {
                "id": 140832950,
                "url": "https://finnhub.io/api/news?id=ac61b8fece0a82acca5929c41d3524911484cfd075f8c84f5e2c80822f18058d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Eli Lilly shares hit a record high Tuesday after IPO stock Kailera Therapeutics posted lackluster test results for its weight-loss pill.",
                "category": "company",
                "datetime": 1783444509,
                "headline": "Eli Lilly's Market Cap Balloons Again On This IPO's Setback"
              },
              {
                "id": 140829898,
                "url": "https://finnhub.io/api/news?id=0add1b096141ec74b3d6cd8f42c09bb8ff6335d4e57ffb6497dbd39245915f1b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Stock Market Today: The Dow Jones index rose, while the Nasdaq dropped amid Samsung earnings. Micron and Sandisk plunged.",
                "category": "company",
                "datetime": 1783444206,
                "headline": "Stock Market Today: Nasdaq Slides As Samsung Tumbles On Earnings; Micron, Sandisk Lose Big (Live Coverage)"
              },
              {
                "id": 140842698,
                "url": "https://finnhub.io/api/news?id=99b1f0500beb2c00b016c007d8ffba03a7d6f93aed2932981bdc1589b960e1a9",
                "image": "https://image.cnbcfm.com/api/v1/image/108331708-17834566151783456613-47020562384-1080pnbcnews.jpg?v=1783456614&w=1920&h=1080",
                "source": "CNBC",
                "related": "LLY",
                "summary": "CNBC's Angelica Peebles reports on Eli Lilly's stock performance.",
                "category": "company",
                "datetime": 1783442598,
                "headline": "Eli Lilly hits 52-week high"
              },
              {
                "id": 140832952,
                "url": "https://finnhub.io/api/news?id=a07c9c4cef97cce487e30f32d0b1056e59bd7c136669ff319a0aef87895b94ee",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "On CNBC’s Mad Dash segment on Monday, July 6, 2026, Jim Cramer made one of his most bullish biotech calls in years, arguing that the sector could be entering a new wave of mergers and acquisitions as the regulatory environment becomes more favorable for dealmaking. “There is a move in biotech that we have not ... Jim Cramer Calls Biotech “The Hottest Group in the Market” as He Predicts “Deals Are Going to Be Flooding the Market”",
                "category": "company",
                "datetime": 1783441817,
                "headline": "Jim Cramer Calls Biotech “The Hottest Group in the Market” as He Predicts “Deals Are Going to Be Flooding the Market”"
              },
              {
                "id": 140831226,
                "url": "https://finnhub.io/api/news?id=94f144166168679378f28a9665f1a5495f8b74e073cab0d967c8a5aa5245a37e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Shares of Eli Lilly have risen by over 40% since the company last reported earnings.",
                "category": "company",
                "datetime": 1783437600,
                "headline": "Eli Lilly Stock Hits a New All-Time High: Has It Gotten Too Expensive to Buy?"
              },
              {
                "id": 140833518,
                "url": "https://finnhub.io/api/news?id=22ce4f0fa67e4136661f31216b954cf91434f87aec814df743617df48808aaad",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1219304819/image_1219304819.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "LLY",
                "summary": "Novo Nordisk A/S is downgraded to Hold as competitive and margin pressures mount and growth slows. Learn more about NVO stock here.",
                "category": "company",
                "datetime": 1783434261,
                "headline": "Novo Nordisk Loses Its Edge, And I'm Downgrading"
              },
              {
                "id": 140831295,
                "url": "https://finnhub.io/api/news?id=3f5c10eed8e8606ed043e3df2f6b863e7bcce6f39900fce931d599a7f1c0dcb7",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "AZN targets continued 2026 growth with expanding blockbuster medicines, a strong pipeline and 2030 revenue goals as it outpaces Pfizer on key metrics.",
                "category": "company",
                "datetime": 1783429260,
                "headline": "Pfizer or AstraZeneca: Which Stock Offers Better Long-Term Potential?"
              },
              {
                "id": 140830043,
                "url": "https://finnhub.io/api/news?id=8357ba81dbd79358869a1770871886a7b1d9d6810dbf75dc63f20d672ac87ab3",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "The stock has surged 160% over the past three years. Meanwhile, two key drugs could continue driving rampant growth.",
                "category": "company",
                "datetime": 1783427400,
                "headline": "Is It Too Late to Buy Eli Lilly Stock? Here's What $1,000 Invested Today Could Be Worth in 10 Years."
              },
              {
                "id": 140832953,
                "url": "https://finnhub.io/api/news?id=0b0e3f54345030becaf6700bd9e31df194ccd771d9fd5ec5d58b3aaac62348f0",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "The funding deal is a vote of confidence in the sales potential of multiple prospects in late-stage development — one of which MeiraGTx recently reacquired from J&J.",
                "category": "company",
                "datetime": 1783426620,
                "headline": "Oberland pours up to $400M into MeiraGTx eye gene therapies"
              },
              {
                "id": 140832954,
                "url": "https://finnhub.io/api/news?id=a263dce72b44aac5f3ccd27014b3814ee84a251c4e6383adc83c7b4c8bb5e79d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "The drug spurred about 10% weight loss over 10 months, though that finding came alongside high rates of gastrointestinal side effects that “alarmed” one analyst.",
                "category": "company",
                "datetime": 1783425592,
                "headline": "Kailera says obesity pill succeeds in late-stage trial in China"
              },
              {
                "id": 140833610,
                "url": "https://finnhub.io/api/news?id=0bdbb88c83cae49361eab3458ab8eaf17cf801bfae72dff0a015223b2b494a87",
                "image": "",
                "source": "Benzinga",
                "related": "LLY",
                "summary": "Eli Lilly Canada announced today that Mounjaro® (tirzepatide), the first and only Health Canada-authorized once-weekly glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor",
                "category": "company",
                "datetime": 1783423485,
                "headline": "Reported Earlier: Eli Lilly's Mounjaro Receives Health Canada Approval To Treat Children 10 Years, Older With Type 2 Diabetes"
              },
              {
                "id": 140829123,
                "url": "https://finnhub.io/api/news?id=37a2108fec9094606f3ebe5d5ff4e2b0ae74d3503d5a4911ba6c5ed9c686f3f7",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "LLY, HSBC and PLTR headline new research as growth drivers, strategic initiatives and key risks shape the latest outlooks for these companies.",
                "category": "company",
                "datetime": 1783419780,
                "headline": "The Zacks Analyst Blog Highlights Eli Lilly, HSBC, Palantir and CBL & Associates"
              },
              {
                "id": 140830464,
                "url": "https://finnhub.io/api/news?id=52f5b12a0e9e9f0e61b5c3a6ed63d8c338dd909d7f128d2ca79318d7e9b6fc10",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2194222724/image_2194222724.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "LLY",
                "summary": "Altimmune, Inc. upgraded to Buy after $535m raise funds Phase 3 MASH trials; pemvidutide data and catalysts vs GLP-1 rivals. Click for this ALT stock update.",
                "category": "company",
                "datetime": 1783419366,
                "headline": "Altimmune: Pemvidutide AUD Data Due Q3 Makes For Intriguing Catalyst - Upgrade"
              },
              {
                "id": 140830465,
                "url": "https://finnhub.io/api/news?id=e0b7e923d5f8e72f7db716b335ec70d8a45cdc7266f8d8f0ebc5eb2bc6f6bc3f",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/464406694/image_464406694.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "LLY",
                "summary": "Q2 of 2026 started with a white-hot rally in the stock market, recovering its losses from the first quarter and setting several record highs throughout April (+10.4%) and May (+5.15).",
                "category": "company",
                "datetime": 1783419120,
                "headline": "Andrew Hill Investment Advisors' Q2 2026 Significant Positions"
              },
              {
                "id": 140832353,
                "url": "https://finnhub.io/api/news?id=a10ad746a2ffa6e59e3235174c29cf20b0bffae400b96c51c0bcba58bdbbd74e",
                "image": "https://image.cnbcfm.com/api/v1/image/108331424-17834307751783430773-47014189223-1080pnbcnews.jpg?v=1783430774&w=1920&h=1080",
                "source": "CNBC",
                "related": "LLY",
                "summary": "CNBC’s Jim Cramer delivers his daily Mad Dash.",
                "category": "company",
                "datetime": 1783416531,
                "headline": "Cramer’s Mad Dash: Eli Lilly"
              },
              {
                "id": 140830044,
                "url": "https://finnhub.io/api/news?id=a525b2f107ac14ff07317a5d0fd2a984f07cf0426b0135b325b8d65da9b43696",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "While rivals scramble to replace lost revenue, Lilly is opening an unprecedented gap by being a “contrarian,” as one expert says.",
                "category": "company",
                "datetime": 1783413771,
                "headline": "Can anyone catch up to Eli Lilly?"
              },
              {
                "id": 140829567,
                "url": "https://finnhub.io/api/news?id=736265c3bcf026a1c9eaf58c5f2d746749e1e592e9b0699d74bef818c0ec74df",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2183695394/image_2183695394.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "LLY",
                "summary": "Novartis bolsters its ADC pipeline via Myricx Bio deal, while Avidity del-brax and Ionis pelacarsen near pivotal readouts—see what to watch now.",
                "category": "company",
                "datetime": 1783413652,
                "headline": "Novartis' Pipeline Building Continues, Pelacarsen Readout Coming Soon"
              },
              {
                "id": 140833611,
                "url": "https://finnhub.io/api/news?id=ab7a1216a78dc201bce1f5d58771f4b687a3ba25225dc733fb08a9eb9a3cfeff",
                "image": "",
                "source": "Benzinga",
                "related": "LLY",
                "summary": "JP Morgan  analyst Chris Schott   maintains Eli Lilly (NYSE:LLY) with a Overweight and raises the price target from $1300 to $1400.",
                "category": "company",
                "datetime": 1783412892,
                "headline": "JP Morgan Maintains Overweight on Eli Lilly, Raises Price Target to $1400"
              },
              {
                "id": 140826482,
                "url": "https://finnhub.io/api/news?id=3a590d94bb8a5e39c7a7de303c8b10521892143450164c440da563676b4aabbc",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Eli Lilly (NYSE:LLY) has entered a new research collaboration with Abbisko Cayman Limited, focused on expanding its pipeline through external R&D partnerships. The company has transferred commercial rights for cancer drug Verzenios in China to Innovent Biologics, adjusting its approach in that market. Eli Lilly has become closely associated with obesity and diabetes treatments, but this latest update shows the company putting more emphasis on partnerships and regional focus. The Abbisko...",
                "category": "company",
                "datetime": 1783394364,
                "headline": "Eli Lilly (LLY) Expands R And D Reach With Abbisko And China Drug Handover"
              },
              {
                "id": 140825341,
                "url": "https://finnhub.io/api/news?id=143fd72effdf00e1ce394af1b2aa7526b7dfbe381380230cd89797d71a5c1cf6",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "In the closing of the recent trading day, Eli Lilly (LLY) stood at $1, denoting a -1.14% move from the preceding trading day.",
                "category": "company",
                "datetime": 1783374306,
                "headline": "Eli Lilly (LLY) Stock Slides as Market Rises: Facts to Know Before You Trade"
              },
              {
                "id": 140824416,
                "url": "https://finnhub.io/api/news?id=58ac94e21051c144761f39b4ccf2c7a30a2aabc76ed7c222a0a92310c75b10a2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Eli Lilly, HSBC and Palantir headline Zacks' latest top stock reports, highlighting growth drivers, opportunities and key risks shaping each outlook.",
                "category": "company",
                "datetime": 1783369560,
                "headline": "Top Stock Reports for Eli Lilly, HSBC & Palantir"
              },
              {
                "id": 140824417,
                "url": "https://finnhub.io/api/news?id=186fff17d3fd8c74d0ea37961a030197361df88d1472c2d1cb324314c6a059a8",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Before the share price caught on, the drugmaker was dealing with a problem most companies only dream of, and it was the clearest sign a surge was building.",
                "category": "company",
                "datetime": 1783369384,
                "headline": "What Eli Lilly Stock Said When It Had Too Much Business"
              },
              {
                "id": 140834190,
                "url": "https://finnhub.io/api/news?id=f3324565e3587a0bf54bca6c0aef4947e4d169260b8a95c59daa073ebddf4393",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Hims & Hers Health shares have surged 45% in 30 days on GLP-1 coverage shifts, but overbought technicals, a Hold rating, and rising short interest suggest a pullback may be near.",
                "category": "company",
                "datetime": 1783362000,
                "headline": "As Employers Drop Obesity Drug Coverage, Hims & Hers Could Be the Winner"
              },
              {
                "id": 140823559,
                "url": "https://finnhub.io/api/news?id=5a144f07bedba347af467925be73da106be1e89722253a4d07e63d464f1aecad",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Healthcare stocks are attractive in a choppy market. These funds, focusing on the broader sector, drugmakers, and biotechs, are worth a look.",
                "category": "company",
                "datetime": 1783361040,
                "headline": "3 Healthcare ETFs to Own in a Choppy Stock Market"
              },
              {
                "id": 140832183,
                "url": "https://finnhub.io/api/news?id=1f8724f063d5dc11fab072e2e81fa24b43a1162feb8cfbde707331beeceeef3e",
                "image": "https://image.cnbcfm.com/api/v1/image/108327424-1782483651570-gettyimages-2283426563-mms23629_eqrvbr4g.jpeg?v=1782483791&w=1920&h=1080",
                "source": "CNBC",
                "related": "LLY",
                "summary": "The Dow Jones Industrial Average hit a fresh all-time intraday high on Tuesday.",
                "category": "company",
                "datetime": 1783360907,
                "headline": "Dow turns red as chip stocks tumble, oil prices gain: Live updates"
              },
              {
                "id": 140822441,
                "url": "https://finnhub.io/api/news?id=a8a1b28066f6e208b8e9c7195cc557e003be78ce757401f35ac4df52844cd88e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Growth premium vs. value recovery, one trades at 33x forward earnings while the other navigates debt reduction and biosimilar expansion.",
                "category": "company",
                "datetime": 1783358941,
                "headline": "Eli Lilly and vs. Teva: Which Pharmaceutical Stock Is a Better Buy in 2026?"
              },
              {
                "id": 140821313,
                "url": "https://finnhub.io/api/news?id=9fe92ea43d36be6f3f609d8d2a019dbf34037595ad1f25b61db9491fca7f39ba",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "As the Nasdaq shakes off a recent spat of volatility, Eli Lilly, Affirm. Twilio and BillionToOne come into focus.",
                "category": "company",
                "datetime": 1783353447,
                "headline": "Lilly, This IPO Leader Among Stocks To Watch In A Mischievous Market"
              },
              {
                "id": 140821033,
                "url": "https://finnhub.io/api/news?id=4c61cc364714533bd4f04c0f59c93534543bbcf3cc26ac7b0713b270e8efaada",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Johnson & Johnson stock is Monday's IBD Stock Of The Day. The medical bellwether will report its June-quarter earnings next week.",
                "category": "company",
                "datetime": 1783352496,
                "headline": "Johnson & Johnson, IBD Stock Of The Day, In Buy Zone Heading Into Earnings"
              },
              {
                "id": 140821034,
                "url": "https://finnhub.io/api/news?id=65c5fe79f348769158d94604c63c830cdd5ebdaaaf0ad0c38b1a70992d53e932",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Abivax (ABVX) shares have rebounded to pre-Phase 3 maintenance data levels as investor concerns over",
                "category": "company",
                "datetime": 1783350767,
                "headline": "Abivax Rebounds, but Obefazimod Unlikely to Replace JAK Inhibitors, Wedbush Says"
              },
              {
                "id": 140822443,
                "url": "https://finnhub.io/api/news?id=e98b4572e6d9ffe70502143f9879e30e50ff8303c76022fdc0e9700f2d9eb925",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "ABBV's Q2 spotlight is on Skyrizi and Rinvoq as rising immunology sales aim to offset Humira's decline ahead of July 31 earnings.",
                "category": "company",
                "datetime": 1783349400,
                "headline": "Will Immunology Franchise Aid AbbVie's Upcoming Q2 Results?"
              },
              {
                "id": 140821035,
                "url": "https://finnhub.io/api/news?id=7fa95457115790ffbd3d459fee8f39e9e781a7aaa3f4b07c34fb7ce24ca002a2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "RiverPark Advisors, an investment advisory firm and sponsor of the RiverPark family of mutual funds, released its “RiverPark Large Growth Fund” Q1 2026 investor letter. A copy of the letter can be downloaded here. The US stock market declined in the quarter with the S&P 500 index (“S&P”) and the Russell 1000 Growth index (“RLG”) […]",
                "category": "company",
                "datetime": 1783348747,
                "headline": "Eli Lilly and Company (LLY) Fell on Regulatory And Pricing Policy Challenges"
              },
              {
                "id": 140824618,
                "url": "https://finnhub.io/api/news?id=1cd268edbc835f22e1ed85b0dc0df50fb53a9d0098a14558c26e1aa4b1f18494",
                "image": "https://cdn.benzinga.com/files/images/story/2025/11/06/aggregated_options_1.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "LLY",
                "summary": "This whale alert can help traders discover the next big trading opportunities.\nWhales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.\nTraders often",
                "category": "company",
                "datetime": 1783344935,
                "headline": "8 Health Care Stocks With Whale Alerts In Today’s Session"
              },
              {
                "id": 140821036,
                "url": "https://finnhub.io/api/news?id=091fa09d558dc0bb8e7d188c4ea5116dfe45df7bf62cba0bf3ee94576ee056cd",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Lilly (LLY) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.",
                "category": "company",
                "datetime": 1783342805,
                "headline": "Investors Heavily Search Eli Lilly and Company (LLY): Here is What You Need to Know"
              },
              {
                "id": 140819146,
                "url": "https://finnhub.io/api/news?id=f25edd9ab45af7d58bc394a2e0c53e3cba34b2b823f1ac2f00fe4ae0eee37a7c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "The weight-loss market is crowded, but this company's lead drug candidate has several key advantages.",
                "category": "company",
                "datetime": 1783337700,
                "headline": "Could This Healthcare Stock Help You Build a Real Fortune Over the Next 20 Years?"
              },
              {
                "id": 140819912,
                "url": "https://finnhub.io/api/news?id=b5d2bd20e0a76d685d7676d5181354c92bbb779edc1b0cc1076343be0a7f6da6",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/628093148/image_628093148.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "LLY",
                "summary": "Discover 5 top Big Pharma stocks amid rising cancer, type 2 diabetes and IMIDs—dividend yields, earnings beats and why they lag AI names. Click for the picks.",
                "category": "company",
                "datetime": 1783331728,
                "headline": "My Top 5 Pharma Stocks Wall Street Ignores"
              },
              {
                "id": 140821903,
                "url": "https://finnhub.io/api/news?id=50d9afed06e6b3f532ca2d55665edd1038daea96dd4f3c25a97bc0e80ba7cea9",
                "image": "https://image.cnbcfm.com/api/v1/image/108330802-17833443451783344342-46993064617-1080pnbcnews.jpg?v=1783344344&w=1920&h=1080",
                "source": "CNBC",
                "related": "LLY",
                "summary": "CNBC’s Jim Cramer delivers his daily Mad Dash.",
                "category": "company",
                "datetime": 1783330243,
                "headline": "Cramer’s Mad Dash: iShares Biotechnology ETF"
              },
              {
                "id": 140818369,
                "url": "https://finnhub.io/api/news?id=4c32b27394b38ba6381a237313ff0ef121847a538c2610757affbb35dc453f7b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Lilly offers investors safety and growth.",
                "category": "company",
                "datetime": 1783330200,
                "headline": "Could Buying Eli Lilly Stock Today Set You Up for Life? (Hint: Yes.)"
              },
              {
                "id": 140820663,
                "url": "https://finnhub.io/api/news?id=963431739cd80c6cb509031afa2f886fe8e816f995942ef106f95370de162f9c",
                "image": "",
                "source": "Benzinga",
                "related": "LLY",
                "summary": "Cantor Fitzgerald  analyst Carter Gould   maintains Eli Lilly (NYSE:LLY) with a Overweight and raises the price target from $1230 to $1350.",
                "category": "company",
                "datetime": 1783327829,
                "headline": "Cantor Fitzgerald Maintains Overweight on Eli Lilly, Raises Price Target to $1350"
              },
              {
                "id": 140816324,
                "url": "https://finnhub.io/api/news?id=394e6d817f0f1e1d3946ce3afe40d22f68f5826a5a03b1edfbb7d09670ef8155",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Eli Lilly (LLY) climbed to new record highs in the final week of June, driven by strong sales of its weight-loss drugs. Away from that spotlight, the drugmaker made changes to a smaller corner of its business in its second-largest market. On June 30, Lilly agreed to hand a Chinese partner full ...",
                "category": "company",
                "datetime": 1783298220,
                "headline": "Lilly quietly hands Chinese partner its cancer drug"
              },
              {
                "id": 140820581,
                "url": "https://finnhub.io/api/news?id=d78c036b50e519b565344311a0d3db62f47be1f8e694fcce308d14cfbc7f99d2",
                "image": "https://cdn.benzinga.com/files/images/story/2026/07/05/Elizabeth-Warren.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "LLY",
                "summary": "Elizabeth Warren warns Trump's law pushed children off Medicaid and CHIP in many states, while also challenging TrumpRx's impact on drug costs.",
                "category": "company",
                "datetime": 1783260507,
                "headline": "Warren Says Trump's Law Pushed 2 Million-Plus Children Off Medicaid, CHIP Across States"
              },
              {
                "id": 140811025,
                "url": "https://finnhub.io/api/news?id=f1e9d64db37cc17e48b64ec74cb4e47eb945bd402723d911b0c3f5a4316d123c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "This biotech might have a bright future, but it'll need to survive against the incumbents to do so.",
                "category": "company",
                "datetime": 1783229100,
                "headline": "How Much Could $1,000 Invested in Viking Therapeutics Be Worth by 2030?"
              },
              {
                "id": 140810623,
                "url": "https://finnhub.io/api/news?id=5b3563dee0c2e0067d9c7222e8655c15df08ec6d9e58e13dbbecdf6e9c5fdf12",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Eli Lilly stock has surged over the past five years, and at around US$1,213 a share, investors are weighing a sharp share price gain against signals that the stock screens as expensive on several checks even as a Discounted Cash Flow (DCF) estimate points to upside. A roughly 441.5% return over five years puts Eli Lilly among the stronger long term performers, which raises the bar for what counts as an attractive entry point. Expectations around the GLP-1 obesity and diabetes franchise can...",
                "category": "company",
                "datetime": 1783221407,
                "headline": "Eli Lilly (LLY) Stock May Trade At A Cash Flow Discount But An Earnings Premium"
              },
              {
                "id": 140808870,
                "url": "https://finnhub.io/api/news?id=4cfa6cb316fb31dbcc6c60b49db48b80587d0e854ad955c1e9f9c51cae161447",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Eli Lilly (NYSE:LLY) and Johnson & Johnson (NYSE:JNJ) just reported Q1 2026 results that read like two different playbooks for winning in healthcare. Lilly is riding a GLP-1 wave. JNJ is proving that a wide, refreshed portfolio can still compound. Both raised guidance and both are worth putting side by side right now. GLP-1 Fireworks ... Dividend King vs. Growth Giant: Johnson & Johnson Takes on Eli Lilly",
                "category": "company",
                "datetime": 1783188027,
                "headline": "Dividend King vs. Growth Giant: Johnson & Johnson Takes on Eli Lilly"
              },
              {
                "id": 140805979,
                "url": "https://finnhub.io/api/news?id=151119961c9183fc98dfd478858adc35b96c4b85974f02c4c5820e14a9cf0302",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "The stock is known to soar on good news.",
                "category": "company",
                "datetime": 1783157400,
                "headline": "Is Viking Therapeutics Stock Going to $50? Here's What the Bulls and Bears Are Saying"
              },
              {
                "id": 140805197,
                "url": "https://finnhub.io/api/news?id=7ebab30bd35d0b44b0b78d9854944513fc2c795ba351b018ff1fa20b3e0e26ae",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2214049905/image_2214049905.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "LLY",
                "summary": "Explore the 4-Factor dividend growth strategy vs SCHD: returns, recent momentum shifts, and a new ROC/PEG variant test.",
                "category": "company",
                "datetime": 1783134898,
                "headline": "SCHD-Inspired 4-Factor Dividend Growth Strategy Selections For July 2026"
              },
              {
                "id": 140804159,
                "url": "https://finnhub.io/api/news?id=eb0bdae932b392a1a0224645bd5ef4d6b9bab66a17109585e57c61183ab4775b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Johnson & Johnson doesn't need GLP-1 drugs to grow, and that's good news for long-term investors.",
                "category": "company",
                "datetime": 1783128900,
                "headline": "Johnson & Johnson Is Walking Away From a $100 Billion Obesity Market. Could That Actually Make It the Better Long-Term Buy Than Eli Lilly?"
              },
              {
                "id": 140799479,
                "url": "https://finnhub.io/api/news?id=570bbb3b7612cc003af58247147d83f6864848d84ec833834a2195433c105740",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Investors are growing more optimistic over the company's pipeline and the initiation of a Phase 1 trial with a new drug.",
                "category": "company",
                "datetime": 1783086339,
                "headline": "Here's Why Viking Therapeutics Stock Surged Higher in June"
              },
              {
                "id": 140802433,
                "url": "https://finnhub.io/api/news?id=62723bd3c7a9defce0d3ae2513b6b9539026160175ddd370ab9c4da81406ba8d",
                "image": "https://cdn.benzinga.com/files/images/story/2025/11/06/aggregated_options_1.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "LLY",
                "summary": "This whale alert can help traders discover the next big trading opportunities.\nWhales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.\nTraders often",
                "category": "company",
                "datetime": 1783085724,
                "headline": "8 Health Care Stocks Whale Activity In Today’s Session"
              },
              {
                "id": 140800008,
                "url": "https://finnhub.io/api/news?id=700a5668d8a7f5f25768a0ea6ab4bddf4389c2f5ed87cbb96053d72b31d8335b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "NVO benefits from Medicare's GLP-1 Bridge, but equal coverage for rival therapies shifts the obesity race toward clinical differentiation and long-term outcomes.",
                "category": "company",
                "datetime": 1783084320,
                "headline": "Can Medicare Bridge Help Novo Nordisk Defend Its GLP-1 Leadership?"
              },
              {
                "id": 140800334,
                "url": "https://finnhub.io/api/news?id=775d6dab566b5db31d75eeaf69c62d346930e076c98148765df6a63feec194c7",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2262213088/image_2262213088.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "LLY",
                "summary": "Hims & Hers' stock rebounded from below $14 after a regulatory shock and is now trading above $37 on a diversified growth narrative. Click to learn more.",
                "category": "company",
                "datetime": 1783078165,
                "headline": "HIMS Breakout Signals Structural Business Transformation"
              },
              {
                "id": 140798353,
                "url": "https://finnhub.io/api/news?id=af3ce6803222543543796d3613fb7b8ebe9f7614e6f6a9734ddef35d29886348",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "[220+ Pages Latest Report] According to a market research study published by Healthcare Foresights, the demand analysis of Global Antidiabetic Drugs Market size & share revenue was valued at approximately USD 103.21 Billion in 2025 and is expected to reach USD 115.02 Billion in 2026 and is expected to reach around USD 309.84 Billion by 2035, at a CAGR of 11.62% between 2026 and 2035. The key market players listed in the report with their sales, revenues and strategies are Eli Lilly and Company,",
                "category": "company",
                "datetime": 1783067400,
                "headline": "[Latest] Global Antidiabetic Drugs Market Size/Share Worth USD 309.84 Billion by 2035 at a 11.62% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)"
              },
              {
                "id": 140800592,
                "url": "https://finnhub.io/api/news?id=69906ae48e307e5378519c5fff630ed122b3c26f7a4c9b4e01447169d34e83d9",
                "image": "https://image.cnbcfm.com/api/v1/image/108330387-17830466841783046680-46921287425-1080pnbcnews.jpg?v=1783046683&w=1920&h=1080",
                "source": "CNBC",
                "related": "LLY",
                "summary": "Alex Zhavoronkov, Founder, CEO & CBO of Insilico Medicine, says the Takeda deal lets the company scale beyond its own pipeline and become a top global player in AI drug discovery. He breaks down the deal's structure, roughly sixty million upfront with the remaining six hundred million tied to milestones and royalties, and points to Insilico's thirty one developmental candidates as proof its platform delivers real drugs, not just software.",
                "category": "company",
                "datetime": 1783033106,
                "headline": "Takeda deal lets us scale our capabilities: Insilico Medicine CEO"
              },
              {
                "id": 140792959,
                "url": "https://finnhub.io/api/news?id=ee6da6462659dfa08361afe62be1aecd7ac76b797f01f38b6a14f5d8d0d35fbe",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "The healthcare giant raised its outlook for the year, yet the market is holding back its reward, creating a tense waiting game for investors.",
                "category": "company",
                "datetime": 1783013373,
                "headline": "JNJ Stock Management Sees A Breakout, The Market Sees A Standoff"
              },
              {
                "id": 140792960,
                "url": "https://finnhub.io/api/news?id=39203cbd19d0e0964e04d51a7e2668f24e017056d2c729bece459fd043d79c36",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Healthcare stocks are attracting attention in a market broadening beyond AI-driven tech names, and now make up a big chunk of the IBD 50 list.",
                "category": "company",
                "datetime": 1783008478,
                "headline": "Healthcare Stocks Rise To The Heart Of IBD's Elite List Of Growth Names"
              },
              {
                "id": 140792961,
                "url": "https://finnhub.io/api/news?id=56ace9e8f9a3601c5c52f7e264cce2da28a30e17b535a2b0bb8be19b8729298e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Five of the biggest names in American pharma just got a deadline from Washington. The House Select Committee on China sent letters this week to Merck (MRK), AbbVie (ABBV), Eli Lilly (LLY), Pfizer (PFE), and Bristol Myers Squibb (BMY), Reuters reported. Lawmakers want each company to explain ...",
                "category": "company",
                "datetime": 1783008180,
                "headline": "House committee investigates Merck, AbbVie over China trials"
              },
              {
                "id": 140800595,
                "url": "https://finnhub.io/api/news?id=d496e3fa576899848e38d53aa49bd5f7bcaf860c9b143f35ea2324fecbf3ac1c",
                "image": "https://image.cnbcfm.com/api/v1/image/108330186-1783019122904-1783018967-46914473154-hd.jpg?v=1783019124&w=1920&h=1080",
                "source": "CNBC",
                "related": "LLY",
                "summary": "Jeff Kilburg, founder and CEO of KKM Financial, joins \"Power Lunch\" to discuss the growing interest in healthcare stocks.",
                "category": "company",
                "datetime": 1783004742,
                "headline": "KKM's Jeff Kilburg explains the healthcare trade in the second half of 2026"
              },
              {
                "id": 140792240,
                "url": "https://finnhub.io/api/news?id=aa7ae8323898ac9799ace5b95b382097f18826aa19687048e1f685b485f1aacd",
                "image": "https://image.cnbcfm.com/api/v1/image/108330088-17830116761783011673-46912650250-1080pnbcnews.jpg?v=1783011675&w=1920&h=1080",
                "source": "CNBC",
                "related": "LLY",
                "summary": "Brad Gerstner, Founder and CEO of Altimeter Capital, joins CNBC's \"Halftime Report” to talk about Trump Accounts launching on July 4th.",
                "category": "company",
                "datetime": 1782998357,
                "headline": "Altimeter's Brad Gerstner on Trump Accounts Launching on July 4th"
              },
              {
                "id": 140800263,
                "url": "https://finnhub.io/api/news?id=f114a66df55bc308a71df96eb51d64a46d1e4cd9f81215e4d1fd64468dcd44c7",
                "image": "https://cdn.benzinga.com/files/images/story/2026/07/02/Doctor-Hand-Point-Patient-Lung-X-ray-Fil.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "LLY",
                "summary": "Abbisko and AstraZeneca will jointly develop a Phase 1/2 NSCLC therapy combining lumipodlin with Tagrisso after China's IND clearance.",
                "category": "company",
                "datetime": 1782997542,
                "headline": "Abbisko, AstraZeneca Team Up on Lung Cancer Drug Combo After China Trial Clearance"
              },
              {
                "id": 140792339,
                "url": "https://finnhub.io/api/news?id=f9dcb503fefd60269c149e9f76bae28991b4905519c4b88be1bdf0e96cf47400",
                "image": "https://cdn.benzinga.com/files/images/story/2026/07/02/NYSE-and-Wall-St.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "LLY",
                "summary": "The Dow hit a record after a weak June jobs report eased Fed rate-hike fears, but a sharp semiconductor rout dragged the Nasdaq 100 lower Thursday.",
                "category": "company",
                "datetime": 1782996982,
                "headline": "Dow Jones Hits Record High as Chip Bloodbath Sinks Nasdaq 100: Stock Market Today"
              },
              {
                "id": 140791356,
                "url": "https://finnhub.io/api/news?id=10cc6cdf9451e8fd98ab98a531cb0ea5c72dfa0d3423e4b2e217404d101249f2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "LLY's leadership in GLP-1 therapies, expanding pipeline and diversified growth strategy support its long-term outlook despite a premium valuation.",
                "category": "company",
                "datetime": 1782996540,
                "headline": "Lilly Up Around 7% in a Week: Should You Buy, Sell or Hold the Stock?"
              },
              {
                "id": 140790463,
                "url": "https://finnhub.io/api/news?id=10f0b33a809a877b563a9f52ce1db4964c98a359ae660cae66a446c49b226eb3",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "GLP-1s will fuel the industry’s growth in the coming years if outside forces don’t get in the way.",
                "category": "company",
                "datetime": 1782984578,
                "headline": "Can pharma sustain its $2T trajectory?"
              },
              {
                "id": 140784654,
                "url": "https://finnhub.io/api/news?id=c32b8d8067a978de3e864c5eed8c51b9f7ac2a4641abd9e48c8b80e4a40fbd6c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Eli Lilly and Company (NYSE:LLY) is one of billionaire Cliff Asness’ top 10 healthcare stock picks. On June 25, Eli Lilly and Company (NYSE:LLY) released additional details about the Medicare GLP-1 Bridge program, where it explained how eligible Medicare Part D patients can access its two weight management drugs for a flat $50 per month […]",
                "category": "company",
                "datetime": 1782941602,
                "headline": "Is Eli Lilly (LLY) One of Billionaire Cliff Asness’ Best Healthcare Stock Picks ?"
              },
              {
                "id": 140782442,
                "url": "https://finnhub.io/api/news?id=a82e2ba1fdf0d4389a81fed4330217d2025311cc1fbb1cd0153cbabe5ff6407a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Our 24/7 Wall St. price target for Eli Lilly (NYSE:LLY) is $1,349.37, pointing to 12.5% upside from a recent price of $1,199.43. We rate LLY a buy with a 90% confidence score. The GLP-1 franchise is compounding faster than the market appreciated last spring, and Foundayo just opened a scalable oral channel to more than ... Eli Lilly Price Prediction: The Case for Double-Digit Upside",
                "category": "company",
                "datetime": 1782926312,
                "headline": "Eli Lilly Price Prediction: The Case for Double-Digit Upside"
              },
              {
                "id": 140792241,
                "url": "https://finnhub.io/api/news?id=26c5b63d838ff9c886771807f4937f9c7d7bdc029a80e7025dd3cc90fb1fe283",
                "image": "https://image.cnbcfm.com/api/v1/image/108329591-17829377401782937737-46894974430-1080pnbcnews.jpg?v=1782937739&w=1920&h=1080",
                "source": "CNBC",
                "related": "LLY",
                "summary": "CNBC’s “Closing Bell Overtime” team discusses whether recent momentum can last in the healthcare trade and how investors can diversify with Ayako Yoshioka, senior investment strategist at Wealth Enhancement.",
                "category": "company",
                "datetime": 1782923971,
                "headline": "Healthcare trade offers demand characteristics not tied to AI: Wealth Enhancement's Yoshioka"
              },
              {
                "id": 140792242,
                "url": "https://finnhub.io/api/news?id=53facab81d989721b5c9369c777ca48725ba2e678cfaaa7c80f49f9fa21a6d57",
                "image": "https://image.cnbcfm.com/api/v1/image/108329580-17829362031782936201-46894576955-1080pnbcnews.jpg?v=1782936202&w=1920&h=1080",
                "source": "CNBC",
                "related": "LLY",
                "summary": "CNBC's Scott Wapner discusses why tech may be primed for a correction with Doug Clinton of Intelligent Alpha.",
                "category": "company",
                "datetime": 1782922254,
                "headline": "Wouldn't be surprised if Nasdaq saw 10% correction, says Intelligent Alpha's Clinton"
              },
              {
                "id": 140780516,
                "url": "https://finnhub.io/api/news?id=3a7b15204a13ad3450467bc3587747bf74035704bb1712cddf2598d1e26d9c36",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "If you sort all the top politicians with a portfolio of above $1 million using their annual gains, who do you expect at the top? Likely Nancy Pelosi, but that’s not the case. A Republican Senator named Ashley Moody has gained 310% in the past year using her portfolio. Her portfolio and her (lack of) ... New Nancy Pelosi? Senator Ashley Moody Up 310% in One Year With These Stocks",
                "category": "company",
                "datetime": 1782921037,
                "headline": "New Nancy Pelosi? Senator Ashley Moody Up 310% in One Year With These Stocks"
              },
              {
                "id": 140792243,
                "url": "https://finnhub.io/api/news?id=45b5c64c99f92da25d0a81cfa20a1a98a379cf5285f0fdf76a67d103398bed57",
                "image": "https://image.cnbcfm.com/api/v1/image/103437310-GettyImages-181179427.jpg?v=1608663124&w=1920&h=1080",
                "source": "CNBC",
                "related": "LLY",
                "summary": "Medicare has started covering obesity drugs for the first time – and companies like Walmart and CVS Health are playing an important role for patients. ",
                "category": "company",
                "datetime": 1782916901,
                "headline": "Healthy Returns: Walmart, CVS step in to help seniors navigate Medicare coverage of obesity drugs "
              },
              {
                "id": 140783647,
                "url": "https://finnhub.io/api/news?id=5066bf226a6e9a856813ce0b0d0da329608b543b7c57933205ecd336be1f3901",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Eli Lilly and Company (LLY) shares up 18,585% since Big Money bought big in 1990.",
                "category": "company",
                "datetime": 1782915791,
                "headline": "Eli Lilly Hits Highs on GLP-1 Medicare Inclusion, Huge Results"
              },
              {
                "id": 140779451,
                "url": "https://finnhub.io/api/news?id=523b2956383e6b450ea7788c809b0fecf4cdb1c62186fa4f1ed46aa648ec5426",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "U.S. lawmakers have opened a national security probe into Eli Lilly's (NYSE:LLY) clinical trial activities in China. The House Select Committee on China is seeking detailed information on trial oversight, data access, and ties to Chinese institutions. Lawmakers have set a July 17 deadline for Eli Lilly to respond with documents and explanations. Eli Lilly is a major global pharmaceutical company with a large portfolio across diabetes, obesity, oncology, immunology, and other therapeutic...",
                "category": "company",
                "datetime": 1782911873,
                "headline": "Eli Lilly (LLY) Faces China Trial Security Probe From U.S. Lawmakers"
              },
              {
                "id": 140791144,
                "url": "https://finnhub.io/api/news?id=296da59202b329e94eb30e441728d2248e767c13e8d3682da006e1acea6629a2",
                "image": "https://cdn.benzinga.com/files/images/story/2026/07/01/Eli-Lilly-and-Co.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "LLY",
                "summary": "Innovent and Eli Lilly sign a China commercialization deal for Verzenios, expanding patient access while Lilly retains manufacturing.",
                "category": "company",
                "datetime": 1782911358,
                "headline": "Innovent, Eli Lilly Partner to Commercialize Breast Cancer Drug in China"
              },
              {
                "id": 140779369,
                "url": "https://finnhub.io/api/news?id=3ce8901c46eab38f26e764781e12116d37a1a7295cb47bd7ff12f69157433a2b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Cathie Wood Loads Up on AI Winners as She Cuts Roku and China Exposure",
                "category": "company",
                "datetime": 1782911072,
                "headline": "Cathie Wood's Biggest Portfolio Moves Reveal Where She's Betting Next"
              },
              {
                "id": 140780654,
                "url": "https://finnhub.io/api/news?id=1bd01f8e61ef51ebcb51cb5b0359bbb686d74196259eb0aebb6161b83b544b3e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "AMGN stands out compared to Biogen given its broader product portfolio, pipeline depth and steadier growth outlook despite patent and competition risks.",
                "category": "company",
                "datetime": 1782911040,
                "headline": "Amgen or Biogen: Which Biotech Stock Appears Better Poised?"
              },
              {
                "id": 140779453,
                "url": "https://finnhub.io/api/news?id=1f0144a5843ade494aec0ed3fa018b39a33281af4aeca74010f3884599175c62",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Eli Lilly and Altria stand out as defensive stock ideas as investors weigh a hawkish Fed, a pivotal jobs report and shifting market leadership.",
                "category": "company",
                "datetime": 1782909240,
                "headline": "Zacks Investment Ideas feature highlights: Eli Lilly and Altria"
              },
              {
                "id": 140779454,
                "url": "https://finnhub.io/api/news?id=c366bf379bb1092d995dc3ee85c652cdae1e7867cc61435044d2b9afd2abe1ca",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Medicare's new GLP-1 coverage could expand access to weight-loss drugs, making ETFs a diversified way to tap growth across the obesity treatment market.",
                "category": "company",
                "datetime": 1782907980,
                "headline": "Weight Loss ETFs Poised to Rally as Medicare Greenlights GLP-1 Coverage"
              },
              {
                "id": 140779455,
                "url": "https://finnhub.io/api/news?id=56407b9333027368b50412c86ef772336e29d20a2ca1742b1e6cd59893752407",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "ARTAN Bio, a longevity biotechnology company based in St. Petersburg, Florida, today announced the close of a $1 million seed round led by company co-founder Michael Torres, Ph.D., following his role as Co-Founder and Chief Executive Officer of CrossBridge Bio through its acquisition by Eli Lilly. The financing will support advancement of ARTAN Bio's proprietary mutation-specific codon suppression platform toward first-in-human development.",
                "category": "company",
                "datetime": 1782907200,
                "headline": "ARTAN Bio Closes $1 Million Seed Round to Advance its tRNA Platform Toward Human Studies"
              },
              {
                "id": 140781140,
                "url": "https://finnhub.io/api/news?id=8fbbc621a8cd4fb575577ee0790b5cbd4701f3005be419ed0d5f09c427524215",
                "image": "https://cdn.benzinga.com/files/images/story/2025/07/10/valuestock_2.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "LLY",
                "summary": "Eli Lilly (NYSE:LLY) has outperformed the market over the past 20 years by 7.2% on an annualized basis producing an average annual return of 16.46%. Currently, Eli Lilly has a market capitalization of $1.06 trillion.",
                "category": "company",
                "datetime": 1782903633,
                "headline": "$100 Invested In Eli Lilly 20 Years Ago Would Be Worth This Much Today"
              },
              {
                "id": 140778355,
                "url": "https://finnhub.io/api/news?id=f858d150b392e08338495fc19b629f0cc19401be2e64d6cdcf4058b11923aa14",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Eli Lilly’s retatrutide has crossed the 30% weight loss benchmark in some patients. Where do GLP-1RAs go from here?",
                "category": "company",
                "datetime": 1782899754,
                "headline": "Beyond the GLP-1RA weight loss ceiling"
              },
              {
                "id": 140778356,
                "url": "https://finnhub.io/api/news?id=e6553d626cfe0811c61def0c4c2f6b1045a7f14eba26bbe2795792dcc6cce600",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Verzenios is a CDK4 and 6 inhibitor that has received approval in China for several indications related to breast cancer.",
                "category": "company",
                "datetime": 1782894734,
                "headline": "Eli Lilly and Innovent agree Verzenios commercialisation deal in China"
              },
              {
                "id": 140779009,
                "url": "https://finnhub.io/api/news?id=7e235737e75307f34990d1801b064b293be3163db461302e6a36048a1c483be2",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2220524615/image_2220524615.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "LLY",
                "summary": "The July 2026 Top 25 High-Growth Dividend Stocks list targets high-quality companies with strong dividend growth and attractive valuations.",
                "category": "company",
                "datetime": 1782894203,
                "headline": "Top 25 High-Growth Dividend Stocks For July 2026"
              },
              {
                "id": 140775242,
                "url": "https://finnhub.io/api/news?id=02b91b29d4d6866e764fad5d9b5d883e4c856174563540aa0f7ce0aaf8483c13",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "The healthcare giant is making waves, but its true value for investors lies in how little it moves with the market.",
                "category": "company",
                "datetime": 1782851051,
                "headline": "Why Is JNJ Stock Defying The Market’s Daily Mood Swings?"
              },
              {
                "id": 140775243,
                "url": "https://finnhub.io/api/news?id=611b3667755b8e730baafdb8b9807052d6b0e7b93d0f01087df26da9b4877386",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Medicare is launching a temporary program that will cover Novo’s Wegovy injection and tablets, as well as Lilly’s Zepbound KwikPen formulation and its Foundayo tablets.",
                "category": "company",
                "datetime": 1782849780,
                "headline": "Medicare GLP-1 Bridge Program Will Pay for Novo, Lilly Drugs"
              },
              {
                "id": 140794987,
                "url": "https://finnhub.io/api/news?id=5ec24d697190f1c28757b334eff89bc95cef699b656004472e841785801e1a0d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Novo Nordisk and Eli Lilly struck a Medicare deal Tuesday that could give their obesity segments a serious boost.",
                "category": "company",
                "datetime": 1782847133,
                "headline": "Medicare Opens the GLP-1 Floodgates for Novo, Eli Lilly"
              },
              {
                "id": 140774479,
                "url": "https://finnhub.io/api/news?id=78e8b5dd1a59f50caffd94f2651b44443b239ce0a607f5daae2fbd722b44d4e6",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Roche won FDA priority review for Enspryng in thyroid eye disease, with a decision date in October and phase III data backing the filing.",
                "category": "company",
                "datetime": 1782845220,
                "headline": "Roche Gets FDA Priority Review for Enspryng in Thyroid Eye Disease"
              },
              {
                "id": 140781615,
                "url": "https://finnhub.io/api/news?id=a41b497352b243f30385a2d53aefb1bce180e1468e1ef5bef606c5f068d620db",
                "image": "https://image.cnbcfm.com/api/v1/image/108328987-17828552841782855282-46874781825-1080pnbcnews.jpg?v=1782855283&w=1920&h=1080",
                "source": "CNBC",
                "related": "LLY",
                "summary": "CNBC's Angelica Peebles to talk Anthropic's new healthcare offering.",
                "category": "company",
                "datetime": 1782841349,
                "headline": "Anthropic launches Claude Science"
              },
              {
                "id": 140773470,
                "url": "https://finnhub.io/api/news?id=29b707e7552d0a70a8c9ae70a8ce5913e3ad8726016f2c23b7119c1377c3a237",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Eli Lilly transferred mainland China commercialization rights for Verzenio to Innovent Biologics.",
                "category": "company",
                "datetime": 1782838956,
                "headline": "Eli Lilly Hands China Sales Rights for Verzenio to Innovent"
              },
              {
                "id": 140773471,
                "url": "https://finnhub.io/api/news?id=b60fbb2c0ce1fb45c8387013f66392ad1bc0f85028dedac5e289199b0afaea57",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "A bipartisan group of United States lawmakers has opened national security investigations into whether five major pharmaceutical companies, including Merck and AbbVie, were involved in clinical trials conducted in China that may have supported the country’s military capabilities, according to a...",
                "category": "company",
                "datetime": 1782836340,
                "headline": "Merck, AbbVie probed by US lawmakers over China clinical trials: report"
              },
              {
                "id": 140773472,
                "url": "https://finnhub.io/api/news?id=dd9f3be263efd64a982febd2eb45d8054e1d87167760cd4440f21992ddf440a3",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "The abbreviated week in the market could set the tone for the back half of 2026.",
                "category": "company",
                "datetime": 1782833880,
                "headline": "Pivotal Week Ahead: Warsh's Hawkish Turn, June Jobs Report on Deck"
              },
              {
                "id": 140772789,
                "url": "https://finnhub.io/api/news?id=de3f318bb1515c1dee051c15eb7470cc6fbc1f3e800340946c3b41a4d183288d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Seven pharma companies have been selected for the FDA PreCheck pilot – a framework intended to bolster the US drug supply chain.",
                "category": "company",
                "datetime": 1782833505,
                "headline": "Lilly and Regeneron amongst first incumbents to FDA’s fast-track facility scheme"
              },
              {
                "id": 140774085,
                "url": "https://finnhub.io/api/news?id=f82c597c7b0224650e59ddbedd837ca5b0705ff6b4b1e9f677918cb5b2ffc780",
                "image": "",
                "source": "SeekingAlpha",
                "related": "LLY",
                "summary": "",
                "category": "company",
                "datetime": 1782829958,
                "headline": "Viking Therapeutics: Updating Pipeline Potential As Oral GLP‑1s Accelerate"
              },
              {
                "id": 140772790,
                "url": "https://finnhub.io/api/news?id=94aa74eb751677e04eddab40996ab91430ca8904551a8a2e394c1da46f66f993",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "LLY is expanding its revenue base beyond Mounjaro and Zepbound with new launches and label expansions that can strengthen long-term growth.",
                "category": "company",
                "datetime": 1782829320,
                "headline": "Can Eli Lilly's New Drugs Fuel Growth Beyond Its GLP-1 Blockbusters?"
              },
              {
                "id": 140772791,
                "url": "https://finnhub.io/api/news?id=34aec002b32bc63d5f61589ce33fa8bdb4921464c5babb6a2030838a8821994e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Innovent will take over importing, marketing, and distributing Verzenios in mainland China as generic competition looms",
                "category": "company",
                "datetime": 1782828638,
                "headline": "Eli Lilly transfers China rights for Verzenios to Innovent Biologics"
              },
              {
                "id": 140771824,
                "url": "https://finnhub.io/api/news?id=e1dd2417e2816b324b2de38909fb8bb300180f32722f54e7aca1ff37b0527d61",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Artificial intelligence is reshaping nearly every industry, but some of its biggest opportunities are emerging far from Silicon Valley. Biotechnology has spent decades producing breakthrough medicines, yet drug development has remained painfully slow, often taking 10 to 15 years while roughly 90% of candidates never reach approval. AI is beginning to change that equation. By ... AI Is Transforming Drug Discovery. Here Is the Next Trillion-Dollar Biotech Opportunity",
                "category": "company",
                "datetime": 1782826709,
                "headline": "AI Is Transforming Drug Discovery. Here Is the Next Trillion-Dollar Biotech Opportunity"
              },
              {
                "id": 140771949,
                "url": "https://finnhub.io/api/news?id=fb6daa8c84b48e87501d79d0012f01b3ffe3345db3bf5c818216b8b82335712a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "SOUTH SAN FRANCISCO, Calif., June 30, 2026--TRexBio Announces Pipeline Progress, Naming TRB-071 as a CD30 Agonist for Immune-Mediated Diseases and Advancement of Lilly-Partnered TRB-051",
                "category": "company",
                "datetime": 1782824400,
                "headline": "TRexBio Announces Pipeline Progress, Naming TRB-071 as a CD30 Agonist for Immune-Mediated Diseases and Advancement of Lilly-Partnered TRB-051"
              },
              {
                "id": 140771950,
                "url": "https://finnhub.io/api/news?id=083f9e2d2a68b906392076d82dd1f219caf6cb1c7fc1470efd969b151eccb29d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Deal gives Innovent commercialization rights in mainland China.",
                "category": "company",
                "datetime": 1782821696,
                "headline": "Eli Lilly Expands China Cancer Reach"
              },
              {
                "id": 140771951,
                "url": "https://finnhub.io/api/news?id=32d382580a359cbe6d7e25b245ddecba242f967a38fed66cddf7d847d7946668",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "- Proceeds will fund advancement of ARON degrader, FX-111, to proof of concept and preclinical development of ARON RIPTAC program - Veteran biotech executive, Anna Protopapas, appointed as CEO to guide company through next phase of growth focused on prostate cancer CAMBRIDGE, Mass., June 30, 2026 (GLOBE NEWSWIRE) -- Flare Therapeutics Inc. (FlareTx), a clinical-stage biotechnology company targeting transcription factors to discover and develop precision medicines, today announced the closing of",
                "category": "company",
                "datetime": 1782820800,
                "headline": "Flare Therapeutics Secures $85M in Insider-Led Series C Financing and Appoints Anna Protopapas as Chief Executive Officer"
              },
              {
                "id": 140771572,
                "url": "https://finnhub.io/api/news?id=b935258c1075a4fd16e03ae08e3de8772954d64711d60721af0c987486266f27",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "The FDA estimates the PreCheck program could save participating companies up to 14 months by reviewing facilities while they are still under construction",
                "category": "company",
                "datetime": 1782817844,
                "headline": "FDA PreCheck pilot program selects Eli Lilly, Regeneron"
              },
              {
                "id": 140772580,
                "url": "https://finnhub.io/api/news?id=a1dbaf2707146a9b63d62e4d0242f6919ac899d858291284c9391b392a71123b",
                "image": "https://cdn.benzinga.com/files/images/story/2026/06/30/Motala--Sweden--7-January-2023-Fda-Logo-.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "LLY",
                "summary": "FDA names seven companies to its PreCheck pilot to speed U.S. drug manufacturing reviews after receiving more than 80 applications.",
                "category": "company",
                "datetime": 1782814640,
                "headline": "Eli Lilly, Regeneron Join FDA Pilot Designed To Accelerate US Manufacturing Readiness"
              },
              {
                "id": 140772368,
                "url": "https://finnhub.io/api/news?id=3baa0b6d8130b52153c4c742a502edc285b76c9502f66aef88dfb9d8fc3d6dd9",
                "image": "",
                "source": "Benzinga",
                "related": "LLY",
                "summary": "- Reuters ",
                "category": "company",
                "datetime": 1782813049,
                "headline": "U.S. House Committee Sends Letters To Pfizer, Eli Lilly & Bristol Myers Squibb Probing China Drug Trials"
              },
              {
                "id": 140774740,
                "url": "https://finnhub.io/api/news?id=bac1556681a38492c41d8ad99cae5880494ce345262ebc615ded85f7f7858fe6",
                "image": "https://cdn.benzinga.com/files/images/story/2026/06/30/Two-Injectors-Dosing-Pens-For-Subcutaneo.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "LLY",
                "summary": "Medicare GLP-1 coverage starts Wednesday. Here’s what patients should know about cost, eligibility and access.",
                "category": "company",
                "datetime": 1782808093,
                "headline": "Getting Wegovy Or Zepbound Through Medicare? Here's What Patients Need To Know Before Coverage Rolls Out Wednesday"
              },
              {
                "id": 140771137,
                "url": "https://finnhub.io/api/news?id=84479ffdcab6081c19c98e41e5559a52d372b160b7cc1f219f95ace9beac9e36",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "SpaceX recently completed a record IPO.",
                "category": "company",
                "datetime": 1782807720,
                "headline": "5 Reasons Eli Lilly Is a Better Stock to Buy Right Now Than SpaceX"
              },
              {
                "id": 140781616,
                "url": "https://finnhub.io/api/news?id=963e113201613b2c8851be69d4c0c869173d8c74ae1382c1c6b8ad9bd0930f03",
                "image": "https://image.cnbcfm.com/api/v1/image/108328618-17828207261782820723-46866154319-1080pnbcnews.jpg?v=1782820725&w=1920&h=1080",
                "source": "CNBC",
                "related": "LLY",
                "summary": "House Select Committee on China Chairman Rep. John Moolenaar (R-Mich.) joins 'Squawk Box' to discuss the committee's probe into pharmaceutical drug testing in China, the U.S.-China AI race, and more.",
                "category": "company",
                "datetime": 1782806491,
                "headline": "Rep. John Moolenaar on China drug trial probe"
              },
              {
                "id": 140781617,
                "url": "https://finnhub.io/api/news?id=595578358436c02ca69098e100d543c131ea3f3936c4b8b6d4cea2efc2233f2e",
                "image": "https://image.cnbcfm.com/api/v1/image/108326901-1782402782515-gettyimages-2282733148-AFP_B8BN4GJ.jpeg?v=1782405357&w=1920&h=1080",
                "source": "CNBC",
                "related": "LLY",
                "summary": "Here are five key things investors need to know to start the trading day.",
                "category": "company",
                "datetime": 1782805099,
                "headline": "SCOTUS decisions, Dow at 52,000, the retirement savings gap and more in Morning Squawk"
              },
              {
                "id": 140770794,
                "url": "https://finnhub.io/api/news?id=f034a1d4005eb11dac136f3e0567ce09b36c8ea64d466de290f5fad4ce74cc69",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "The weight loss tailwind isn't about to come to a halt.",
                "category": "company",
                "datetime": 1782804000,
                "headline": "Eli Lilly Is Dominating the GLP-1 Market: Here's What a $5,000 Investment Could Look Like in 5 Years"
              },
              {
                "id": 140781619,
                "url": "https://finnhub.io/api/news?id=291ce5f788bf8dd57f6e9545263698fee9fbfed8374837611199f6ec68f6d288",
                "image": "https://image.cnbcfm.com/api/v1/image/108328219-1782751789876-gettyimages-2279484892-64393_48_ms_4772.jpeg?v=1782751835&w=1920&h=1080",
                "source": "CNBC",
                "related": "LLY",
                "summary": "GLP-1 drugs have remained out of reach for many Americans on Medicare due to their cost. A new pilot program launching July 1 is changing that. CNBC’s Annika Constantino has the details.",
                "category": "company",
                "datetime": 1782795601,
                "headline": "This new Medicare program offers obesity drugs for $50 a month. Here’s what you need to know"
              },
              {
                "id": 140781618,
                "url": "https://finnhub.io/api/news?id=c2b9cf7db5e8e7b511f80cba972d4339f22d420c6b2bd7054751c0b254645eec",
                "image": "https://image.cnbcfm.com/api/v1/image/108139249-17461007952025-05-01t110135z_141929000_rc26x7av6mkm_rtrmadp_0_health-obesity-who.jpeg?v=1746100832&w=1920&h=1080",
                "source": "CNBC",
                "related": "LLY",
                "summary": "The move could unlock millions of new patients for Novo Nordisk and Eli Lilly and expand access to medications that were previously out of reach for seniors.",
                "category": "company",
                "datetime": 1782795601,
                "headline": "Medicare will start covering obesity drugs for the first time. Here's what patients should know"
              },
              {
                "id": 140770892,
                "url": "https://finnhub.io/api/news?id=05246e7da56482fd9c0ae977b47c6c3ec2861ee07f3fd46d27d4251486845dee",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2218794567/image_2218794567.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "LLY",
                "summary": "Eli Lilly is leveraging its exceptional cash flow to build an AI-native drug discovery and manufacturing platform. Read why LLY stock is a Buy.",
                "category": "company",
                "datetime": 1782792148,
                "headline": "Forget Weight Loss: Eli Lilly's Real Upside Is As An AI Compounder"
              },
              {
                "id": 140770055,
                "url": "https://finnhub.io/api/news?id=91caaf967e4e00447d29efbb9f75d04a99c1b8a44db04f93d8c2e88d41cfba9c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Innovent Biologics, Inc. (\"Innovent\") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ophthalmology and other major disease areas, and Eli Lilly and Company (NYSE: LLY) today jointly announced that they have entered into a distribution and promotion agreement regarding Lilly's CDK4 & 6 inhibitor Verzenios® (abemaciclib) in mainland China:",
                "category": "company",
                "datetime": 1782792000,
                "headline": "Innovent Biologics and Lilly Enter into Commercialization Agreement for Verzenios® (abemaciclib) in Mainland China"
              },
              {
                "id": 140770030,
                "url": "https://finnhub.io/api/news?id=81ce98efceb6118248cb9b613d0be40760b83b7832377ce78f03489c72a297a3",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Micron is now 1.9% of the benchmark index in terms of weight.",
                "category": "company",
                "datetime": 1782790814,
                "headline": "MU Stock Caps Best First Half Ever With 4x Surge, Cracks S&P 500’s Top 10: Retail Bulls Want More"
              },
              {
                "id": 140022502,
                "url": "https://finnhub.io/api/news?id=c4b2508893fdf859eedbbcbdca73acab77fea0fe8f3254adf710144e808f6c4b",
                "image": "",
                "source": "Benzinga",
                "related": "LLY",
                "summary": "",
                "category": "company",
                "datetime": 1782788830,
                "headline": "Reported Earlier, HUTCHMED And Innovent Secure NDA Review In China For Fruquintinib–Sintilimab In Patients Failing Prior TKI Treatment"
              },
              {
                "id": 140769321,
                "url": "https://finnhub.io/api/news?id=71d4561fdeb6df32b59141316bb4ecaa108f3954e0a39cd00bec2edc34f531ec",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Given its significant hedge fund backing and attractive upside potential, NVIDIA Corporation (NASDAQ:NVDA) is one of the most promising robotics stocks. NVIDIA Corporation (NASDAQ:NVDA) is extending its physical AI ambitions on two fronts simultaneously, pushing deeper into industrial robotics safety while advancing its push into agentic life sciences. On June 23, 2026, NVIDIA Corporation (NASDAQ:NVDA) […]",
                "category": "company",
                "datetime": 1782785057,
                "headline": "NVIDIA (NVDA) Among The Most Promising Robotics Stocks; Here’s Why"
              },
              {
                "id": 140767824,
                "url": "https://finnhub.io/api/news?id=0c7269fd6125af4ddaf4b43c552b73a8810687b2800e66dd9146bbbc4f6d1075",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "The latest trading day saw Eli Lilly (LLY) settling at $1, representing a +1.81% change from its previous close.",
                "category": "company",
                "datetime": 1782769503,
                "headline": "Eli Lilly (LLY) Outpaces Stock Market Gains: What You Should Know"
              },
              {
                "id": 140765416,
                "url": "https://finnhub.io/api/news?id=95a85c6616a1501f68624ef59ae95118582b4bae62be2a70cc74e23ab2cfc456",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "AbbVie (ABBV) - a pharmaceutical company developing and selling specialized therapies - hit a 5-day winning streak, with cumulative gains over this period amounting to 17%. The company's market cap has surged by about $65 Bil over the last 5 days and currently stands at $448 Bil.",
                "category": "company",
                "datetime": 1782758026,
                "headline": "AbbVie Stock Rockets 17% With 5-Day Winning Streak"
              },
              {
                "id": 140765417,
                "url": "https://finnhub.io/api/news?id=54fca79a72ef6ab10f321f3b9a76224d1539a3dba8e92484bc7fdf1e835ee63d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "This pharma giant's recent run is grabbing headlines, but its long-term behavior tells a more interesting story about portfolio risk.",
                "category": "company",
                "datetime": 1782754652,
                "headline": "Should You Chase The Breakout In Eli Lilly Stock?"
              },
              {
                "id": 140766531,
                "url": "https://finnhub.io/api/news?id=e9a2d8df8fe3d265cae855305ce25afe0c53a9bb633ad80629a2843f33f5b8a6",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2220268222/image_2220268222.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "LLY",
                "summary": "Sector outlook for 2H 2026: XLK downgraded, XLI/XLU upgraded, XLY/XLC underperform. Click here to read the analysis in detail.",
                "category": "company",
                "datetime": 1782754200,
                "headline": "My S&P 500 Prediction On Sector Outperformers And Underperformers For 2H/2026"
              },
              {
                "id": 140766217,
                "url": "https://finnhub.io/api/news?id=488e3e2c93c13800334fb14b1876f80a9a8aa7c1ac7f6c72ca089bd9f5f3ff34",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2241146296/image_2241146296.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "LLY",
                "summary": "Big pharma’s patent cliff may be overstated: layered IP, incremental innovation, and smart licensing extend exclusivity and growth. Click here to read more.",
                "category": "company",
                "datetime": 1782752400,
                "headline": "Big Pharma's Looming Patent Cliff Period And How It Is Trying To Address It"
              },
              {
                "id": 140763997,
                "url": "https://finnhub.io/api/news?id=acfe0005c1f77e002d431991c8fd15ae43e1891dc94af4b3a32bb943821c4723",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "NVO and VKTX stocks offer contrasting opportunities in the fast-growing obesity market, with key differences in growth, risk and pipeline strength.",
                "category": "company",
                "datetime": 1782745800,
                "headline": "Novo Nordisk vs. Viking: Which Obesity Drug Stock Is the Better Buy?"
              },
              {
                "id": 140763996,
                "url": "https://finnhub.io/api/news?id=f241264e1ae813d3d1334adca34d4c30f747d2ac81b88d7e5865f733236d5d8a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "LLY, ABBV, BIIB and JNJ hit new 52-week highs as biotech rallies, with company-specific pipeline, approvals and deal activity adding momentum.",
                "category": "company",
                "datetime": 1782745800,
                "headline": "Biotech Bigwigs ABBV, JNJ, BIIB & LLY Hit New 52-Week Highs"
              },
              {
                "id": 140767078,
                "url": "https://finnhub.io/api/news?id=16a890f2d949d02699e5446ef6360f37c8e0299f410432efe38abbe7227fd3f1",
                "image": "",
                "source": "Benzinga",
                "related": "LLY",
                "summary": "https://www.cnbc.com/2026/06/29/eli-lilly-regeneron-in-fda-precheck-manufacturing-program.html?&qsearchterm=eli%20lilly",
                "category": "company",
                "datetime": 1782744903,
                "headline": "'Eli Lilly, Regeneron Among First Companies Selected For FDA Initiative To Speed Review Of New Manufacturing Facilities' - CNBC"
              },
              {
                "id": 140781620,
                "url": "https://finnhub.io/api/news?id=b6f68c2f88eb4507260ba26dbf69e3ee5ebe1e97e15071c48a33ba6ef608e712",
                "image": "https://image.cnbcfm.com/api/v1/image/108203002-17586586832025-09-23t201602z_1200746466_rc2oxgauogov_rtrmadp_0_usa-lilly.jpeg?v=1782769813&w=1920&h=1080",
                "source": "CNBC",
                "related": "LLY",
                "summary": "Eli Lilly and Regeneron are among the first seven companies the FDA has selected for its PreCheck Pilot Program, CNBC has learned.",
                "category": "company",
                "datetime": 1782744603,
                "headline": "Eli Lilly, Regeneron among first companies selected for FDA initiative to speed review of new manufacturing facilities"
              },
              {
                "id": 140762551,
                "url": "https://finnhub.io/api/news?id=97b036c0a0bd67d50a2c6a3f2070fb7724a4dd6463a6edf516fdbbae908fdf80",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "The Nasdaq recorded its fifth straight day of losses on Friday, while the S&P 500 ended marginally lower, with AI-related chip stocks taking a hit, as investors rotated out of major tech stocks and took refuge in defensive assets.",
                "category": "company",
                "datetime": 1782739680,
                "headline": "Stock Market News for Jun 29, 2026"
              },
              {
                "id": 140762552,
                "url": "https://finnhub.io/api/news?id=388fcf6dadc86ecd1512d77453adb904d121387200cd730d5085356763d5d64f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "LLY hit a record high after a positive EU panel opinion for Jaypirca and expanded $50/month Medicare access for Zepbound and Foundayo.",
                "category": "company",
                "datetime": 1782739620,
                "headline": "Here's Why Shares of Eli Lilly Hit an All-Time High on Friday"
              },
              {
                "id": 140771952,
                "url": "https://finnhub.io/api/news?id=c4be32442953f971cc08b8efa1ad4f529b6b67416f847037d6baa05b99ef37be",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "As AI stocks face volatility, capital is rotating into biotech, industrials, utilities, consumer staples, and dividend ETFs showing relative strength.",
                "category": "company",
                "datetime": 1782739200,
                "headline": "5 Places Investors Can Hide If the AI Trade Keeps Cracking"
              },
              {
                "id": 140763353,
                "url": "https://finnhub.io/api/news?id=1f7f419f3bbad927aef061ca6d26d67e1cd18b1b1b987034a5656bdefd9c12f3",
                "image": "https://image.cnbcfm.com/api/v1/image/108328213-17827514121782751407-46849797479-1080pnbcnews.jpg?v=1782751411&w=1920&h=1080",
                "source": "CNBC",
                "related": "LLY",
                "summary": "CNBC's \"Halftime Report\" team debate the end of the quarter and discuss their trading strategy heading into the second half of the year.",
                "category": "company",
                "datetime": 1782738106,
                "headline": "'Halftime' traders debate the market setup for the next half of 2026"
              },
              {
                "id": 140761566,
                "url": "https://finnhub.io/api/news?id=50b3a8423c19bf5197bdb785ca5d68222f40cdd10bf5460234517bb284f91695",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Why investing for the long run, especially if you buy certain popular stocks, could reap huge rewards.",
                "category": "company",
                "datetime": 1782736215,
                "headline": "Here's How Much a $1000 Investment in Eli Lilly Made 10 Years Ago Would Be Worth Today"
              },
              {
                "id": 140761567,
                "url": "https://finnhub.io/api/news?id=e4fd842930c69b4cb1219cad2efac884044ac9b9e4bb65154af4b5903dc71e21",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Lilly (LLY) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.",
                "category": "company",
                "datetime": 1782733560,
                "headline": "Lilly (LLY) Moves 7.1% Higher: Will This Strength Last?"
              },
              {
                "id": 140761245,
                "url": "https://finnhub.io/api/news?id=47c14cf1e84950a3a28b648c3734658b98b16788d3e9506ece04e8e386776285",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1029203886/image_1029203886.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "LLY",
                "summary": "TG Therapeutics, Inc. boosts anti-CD20 share as Q1 revenue jumps 69.6% to $204.9M, but overbought signals hint at a near-term pullback. Click for this TGTX update.",
                "category": "company",
                "datetime": 1782723855,
                "headline": "TG Therapeutics Surged 88%: Time To Be More Careful (Rating Downgrade)"
              },
              {
                "id": 140759882,
                "url": "https://finnhub.io/api/news?id=6314d5e4a4a0c24bb6774fb1a64d0e8db7e109083f268fcd52e2286a11e8846a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Eli Lilly and Company (NYSE:LLY) is one of the Stocks That Will Make You Rich Over the Next 3 Years. Eli Lilly and Company (NYSE:LLY) has gained roughly 6% over the past 30 days, and the Street expects more than 13.6% upside from the current level. Recently, on June 25, Leerink analyst David Risinger raised […]",
                "category": "company",
                "datetime": 1782719727,
                "headline": "Eli Lilly and Company (LLY) Up More Than 6% Over the Past Month, Can it Move Higher?"
              },
              {
                "id": 140757924,
                "url": "https://finnhub.io/api/news?id=729a2c31b9f4a6613a413c8aee3ccaec056aee19ad828a7cd2b5341438f3325e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Harbour BioMed (the \"Company\"; HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology, oncology and other disease areas, today announced the appointment of Dr. Lloyd Klickstein as Scientific Advisor for Immunology.",
                "category": "company",
                "datetime": 1782696420,
                "headline": "Harbour BioMed Appoints Dr. Lloyd Klickstein as Scientific Advisor for Immunology"
              },
              {
                "id": 140757296,
                "url": "https://finnhub.io/api/news?id=ce6af60991a8b0d627792b7e3d525c957e6d8d5bd78a906834ac9f40afe5ffa6",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "The U.S. and Iran reportedly have agreed to halt tit-for-tat attacks. Tesla sales and the June jobs report on are on tap.",
                "category": "company",
                "datetime": 1782690165,
                "headline": "Dow Jones Futures Rise On U.S.-Iran News; Market At Tipping Point"
              },
              {
                "id": 140756650,
                "url": "https://finnhub.io/api/news?id=7c5df493acb477f56491149794859fbf4f25325b6da70f3861e014bf8f873ed9",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Eli Lilly and Company (NYSE:LLY) is among the Best Healthcare Stocks Stocks. On June 23, Reuters reported that Eli Lilly and Company (NYSE:LLY) expects to launch its oral weight-loss drug across Europe and Britain in the second half of 2026 or early 2027. Executive Vice President Patrik Jonsson said the company will start targeting patients paying […]",
                "category": "company",
                "datetime": 1782676668,
                "headline": "Is Eli Lilly and Company (LLY) Among the Best AI-Powered Healthcare Stocks to Buy According to Hedge Funds?"
              },
              {
                "id": 140754949,
                "url": "https://finnhub.io/api/news?id=3e5599853a9c4dbbcf68ee065dda2d530709689c69fcd984f2cce08c9ac7965a",
                "image": "https://image.cnbcfm.com/api/v1/image/108327550-1782492280306-gettyimages-2278151752-dsc00398.jpeg?v=1782492397&w=1920&h=1080",
                "source": "CNBC",
                "related": "LLY",
                "summary": "Demand for whey protein is off the charts as American diet trends change and GLP-1s boom, and the dairy industry is struggling to produce enough.",
                "category": "company",
                "datetime": 1782644731,
                "headline": "America can't get enough of protein. The dairy industry can't keep up"
              },
              {
                "id": 140754956,
                "url": "https://finnhub.io/api/news?id=5c331015c13885663587ad1ccc4ea91905820b7042264ca4eb59df742b3639b1",
                "image": "https://image.cnbcfm.com/api/v1/image/106340566-1579197686151gettyimages-172600009.jpeg?v=1782479781&w=1920&h=1080",
                "source": "CNBC",
                "related": "LLY",
                "summary": "Many seniors may be unaware of the landmark coverage shift starting on July 1, with limited advertising seen from the government or Eli Lilly and Novo.",
                "category": "company",
                "datetime": 1782633601,
                "headline": "Seniors in Medicare are about to get landmark obesity drug coverage — but many may not know it yet"
              },
              {
                "id": 140753382,
                "url": "https://finnhub.io/api/news?id=32db7e2ecdb996c42e47ecaa7c60502bc045677130c21d2bbf26755ffc554e1a",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2217097273/image_2217097273.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "LLY",
                "summary": "Eli Lilly stock surged 7% as healthcare rallies; explore its oncology & neuroscience catalysts, risks from price cuts, and 2026 upside—Click for more on LLY stock.",
                "category": "company",
                "datetime": 1782629424,
                "headline": "Why Eli Lilly Gained 7% On Friday"
              },
              {
                "id": 140748166,
                "url": "https://finnhub.io/api/news?id=fc079b85ed59e2ec2b354a1e6fc75a1ec4655500cc7c15c0c15f6f1c20c6737c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Eli Lilly and Company (NYSE:LLY) is one of the top trending US stocks to buy now. Eli Lilly and Company (NYSE:LLY) and BioArctic AB announced on June 22 their entry into a research and collaboration agreement regarding a potential new treatment combining BioArctic’s proprietary BrainTransporter technology with an undisclosed Lilly drug candidate in neurodegeneration. Management […]",
                "category": "company",
                "datetime": 1782588092,
                "headline": "Eli Lilly (LLY) and BioArctic AB Enter into Research and Collaboration Agreement"
              },
              {
                "id": 140748167,
                "url": "https://finnhub.io/api/news?id=0ff6346897140395f192ca5cf2c77f410394ef667635e7433763b5a1b0efeca5",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Eli Lilly and Company (NYSE:LLY) is one of the safe stocks for beginners to buy in 2026. Eli Lilly and Company (NYSE:LLY) received a rating update from Leerink on June 25. The firm lifted the price target on the stock to $1,232 from $1,119 and maintained an Outperform rating on the shares. In a separate development, […]",
                "category": "company",
                "datetime": 1782585388,
                "headline": "Here’s What the Street Thinks About Eli Lilly and Company (LLY)"
              }
            ],
            "data_source": "finnhub_news_keyword_model",
            "article_count": 8,
            "negative_hits": 1,
            "positive_hits": 1,
            "recomputed_at_score": true,
            "sentiment_score_raw": 0,
            "source_article_count": 250,
            "discarded_article_count": 224
          },
          "sentimentPoints": 2
        }
      },
      "技術信號": {
        "max": 30,
        "raw": 16.9,
        "grade": "較差",
        "items": {
          "bbPoints": 2.4,
          "adxPoints": 3,
          "sarPoints": 1.2000000000000002,
          "vcpPoints": 2.2,
          "macdPoints": 2.4,
          "vcpPayload": {
            "vcp_pass": false,
            "vcp_score": 2.2,
            "vcp_reason": "波幅收縮(17.1%→9.4%)；跌縮量(近10日6日)；站上MA50；Ready=Y；Confirm=N",
            "vcp_metrics": {
              "up_days": 3,
              "vol_ref": 3143160,
              "down_days": 6,
              "vcp_ready": true,
              "above_ma50": true,
              "avg_vol_10": 2644520,
              "avg_vol_20": 3106705,
              "avg_vol_30": 3143160,
              "range_pct_10": 0.0939904493875163,
              "range_pct_20": 0.1471805556678331,
              "range_pct_30": 0.17058518911078172,
              "up_expand_ok": false,
              "lookback_used": 59,
              "near_20d_high": false,
              "contraction_ok": true,
              "down_shrink_ok": true,
              "up_expand_days": 1,
              "breakout_20d_ok": false,
              "vol_ratio_10_30": 0.841357105588007,
              "dist_to_20d_high": 0.07430749827153937,
              "down_shrink_days": 6,
              "breakout_level_20d": 1249.44995,
              "vcp_breakout_confirm": false,
              "contraction_ratio_10_30": 0.5509883353734589
            },
            "vcp_name_en": "Volatility Contraction Pattern",
            "vcp_name_zh": "波動收縮形態",
            "vol_contraction": true
          },
          "kdjAdxPoints": 0.5,
          "rsiKdjPoints": 2.4,
          "volumeWeight": 2,
          "maCrossPoints": 1.6,
          "shortRsiPoints": 0,
          "shortMacdPoints": 0.4,
          "volConfirmPoints": 0,
          "volumePointsTechnical": 0.8
        }
      },
      "風險管理": {
        "max": 10,
        "grade": "一般",
        "items": {
          "position": {
            "score": 1.5,
            "details": {
              "atrPct": 3.5403485775131203,
              "turnoverUsdM": 3510.09354319545,
              "liquidityPoints": 0.8,
              "volatilityPoints": 0.7
            }
          },
          "rrPoints": 1.4,
          "stopLevels": {
            "symbol": "US.LLY",
            "rr_range": "1:1.0-1:2.5",
            "risk_profile": "中等",
            "stop_loss_price": 1074.7107,
            "strength_details": {
              "ma_score": 1.5,
              "atr_score": 1,
              "rsi_score": 2,
              "macd_score": 1.5,
              "volume_score": 1
            },
            "market_adjustment": 1,
            "risk_reward_ratio": 1,
            "stop_loss_percent": 7.1,
            "take_profit_price": 1218.8473,
            "target_multiplier": 1.6,
            "technical_strength": 1.43,
            "take_profit_percent": 5.4
          },
          "positionPoints": 1.5,
          "stopLossPoints": 1.2,
          "diversification": {
            "score": 2,
            "details": {
              "method": "sector concentration proxy; no portfolio holdings used",
              "sector": "Health Care",
              "concentratedSectorPenalty": 0
            }
          },
          "riskRewardRatio": 1.2,
          "stopLossPercent": 7.0806971550262405,
          "diversificationPoints": 2
        }
      }
    }
  },
  "modelVersion": "cursor_18_27_news_v2_160",
  "providerErrors": [],
  "rankingScoreMax": 160,
  "dataCompleteness": {
    "complete": true,
    "missingFields": [],
    "optionalInputs": [
      "institutionalData"
    ],
    "requiredInputs": [
      "fundamentals",
      "marketContext.VIX",
      "marketContext.SPY",
      "marketContext.QQQ",
      "catalystData",
      "sentimentData",
      "ATR",
      "sector"
    ],
    "optionalInputWarnings": []
  },
  "technicalIndicators": {
    "adx": 92.86,
    "atr": {
      "atr": 40.9479,
      "rule": "ATR / current price; lower volatility scores higher",
      "score": 4,
      "atr_pct": 3.54
    },
    "cci": {
      "rule": "Cursor_18.24 CCI bands",
      "level": "弱勢",
      "score": 4,
      "value": -28.6
    },
    "cmf": {
      "rule": "Cursor_18.24 CMF bands",
      "level": "平衡",
      "score": 4,
      "value": 0.0565
    },
    "kdj": {
      "d": 44.43,
      "j": -2.46,
      "k": 28.8,
      "rule": "Cursor_18.24 K/D cross",
      "score": 0,
      "signal": "死叉"
    },
    "mfi": {
      "rule": "Cursor_18.24 MFI bands",
      "level": "弱流入",
      "score": 4,
      "value": 46.84
    },
    "obv": {
      "rule": "Cursor_18.24 recent_slope vs previous_slope",
      "score": 4,
      "trend": "弱勢",
      "value": 14584621,
      "recentSlope": -33037.9,
      "previousSlope": 1010940
    },
    "rsi": 56.31,
    "sar": {
      "rule": "Cursor_18.24 Parabolic SAR",
      "score": 4,
      "trend": "下降",
      "value": 1247.2758,
      "position": "SAR喺價上",
      "distancePct": 7.84,
      "previousTrend": "下降"
    },
    "ma50": 1101.5919,
    "macd": {
      "macd": 23.408504349264376,
      "trend": "中性偏多",
      "signal": 32.5754791544573,
      "histogram": -9.166974805192922
    },
    "vwap": {
      "rule": "Cursor_18.24 VWAP 20D consecutive close",
      "score": 2,
      "value": 1168.0424,
      "position": "<VWAP",
      "consecutiveAbove": 0
    },
    "volume": {
      "rule": "Cursor_18.24 volume ratio",
      "level": "無力",
      "ratio": 0.98,
      "score": 4,
      "avgVolume": 3100086,
      "currentVolume": 3034821
    },
    "derived": {
      "ma20": 1168.9153,
      "ma50": 1101.5919,
      "prevClose": 1152.54,
      "avgVolume10": 2575642,
      "avgVolume20": 3100086,
      "changePercent": 0.35,
      "avgVolumeForScore": 3100086
    },
    "ma_cross": {
      "ma20": 1168.9153,
      "ma50": 1101.5919,
      "rule": "Cursor_18.24 MA20/MA50 cross",
      "cross": "多頭",
      "score": 4,
      "prevMa20": 1167.5525,
      "prevMa50": 1097.7264,
      "spreadPct": 6.11,
      "isVolumeBreakout": false
    },
    "bollinger": {
      "lower": 1076.5779,
      "upper": 1261.2528,
      "position": "中間"
    },
    "rsi_short": 5.81,
    "macd_short": {
      "macd": 0,
      "trend": "中性",
      "signal": 0,
      "histogram": 0
    },
    "volume_ratio": {
      "ratio": 0.98
    }
  }
}

{
  "close": 1156.61,
  "volume": 3034821,
  "changePercent": 0.35
}